IND-Enabling Preclinical Studies of [11C]COU, a Trapped Metabolite PET Radiotracer for Monoamine Oxidase-B

IND-Enabling Preclinical Studies of [11C]COU, a Trapped Metabolite PET Radiotracer for Monoamine Oxidase-B | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article IND-Enabling Preclinical Studies of [11C]COU, a Trapped Metabolite PET Radiotracer for Monoamine Oxidase-B Madison Frazier, Tanpreet Kaur, Jenelle Stauff, Wade P. Winton, and 8 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7762445/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 05 Nov, 2025 Read the published version in Medicinal Chemistry Research → Version 1 posted 4 You are reading this latest preprint version Abstract [ 11 C]COU is a trapped metabolite radiotracer for in vivo analysis of Monoamine Oxidase B activity using positron emission tomography (PET) imaging. [ 11 C]COU has the potential to quantify astrocytosis in the early stages of Alzheimer’s disease, providing an earlier marker of disease than currently available for staging disease progression. Prior preclinical studies have demonstrated the efficacy of this radiotracer in preclinical imaging studies, warranting the translation for clinical evaluation. In this paper, we describe results of the requisite preclinical studies required to obtain approval for translation of [ 11 C]COU into first-in-human studies. Development and validation of a production method that conforms to the quality requirements described in the US Pharmacopeia was accomplished, along with preclinical rodent studies to determine human radiation dose estimates and a single acute dose pharmacology and toxicology study to establish that an injected mass dose 100-fold higher than the proposed PET imaging dose was below the no-observed-adverse-effect level (NOAEL). The production method was validated in triplicate, yielding [ 11 C]COU in sufficient radiochemical yield (9.3 ± 0.008%), radiochemical purity (99.2 ± 0.002%) and molar activity (4471 ± 1744 Ci/mmol) for routine clinical use, and providing a product that was sterile and met (or exceeded) all quality control requirements for human use. Dosimetric analysis determined that the effective human dose of [ 11 C]COU is 0.005mSv/MBq, also acceptable for clinical use. Lastly, no observable adverse effects were noted at 86 µg/kg in rodent toxicology studies (100x the proposed human dose). From these results we received approval to advance [ 11 C]COU into clinical studies. PET imaging Preclinical study MAO-B Synthesis validation Dosimetry Pharmacology/Toxicology Figures Figure 1 Figure 2 Figure 3 INTRODUCTION As the global population ages, the incidence of Alzheimer’s Disease and related dementias (ADRD) is expected to increase, thus the need for earlier clinical diagnosis is essential 1 . The current standard of care involves measuring amyloid β (Aβ) plaques and tau neurofibrillary tangles (NFTs) either through blood tests or Positron Emission Tomography (PET) imaging 2 . Treatments to alleviate Aβ burden, lecanemab and donanemab, are effective at removing plaques from the brain and have recently received FDA approval for treatment of AD. However, when Aβ and tau accumulation become measurable, neuronal impairment and loss has already begun and thus alleviation of symptoms with these treatments is somewhat limited, yet disease progression has been slowed with the use of these new drugs. The process of plaque deposition and NFT formation have been shown to begin years before symptoms arise in ADRD 3 – 7 . Due to this disconnect in disease onset and diagnosis, many researchers have begun to look for other biomarkers that can be detected earlier in AD progression. Currently the earliest detectable change in patients who will go on to develop AD is neuroinflammation 3 , 4 . There are two cells that play a role in this process, microglia and astrocytes 8 . Normally these cells maintain the homeostasis of the neurological system by keeping ions in balance, metabolizing neurotransmitters, and maintaining the blood-brain barrier (BBB) 9 . However, as Aβ fibrils begin to build up in the brain, these cells become hyperactivated in a process called gliosis or astrocytosis 10 . As neuroinflammation emerges as an early biomarker of ADRD, and modulating immune responses is considered as a potential therapeutic strategy, there is growing interest in quantifying neuroinflammation in ADRD via PET imaging. 8 , 11 , 12 Several approaches have used PET to detect activated microglia. For example, the translocator protein 18 kDa (TSPO), expressed on activated microglia, has been widely used for the quantification of neuroinflammation in AD 13 . Evidence suggests microglial activation precedes regional tau and neurodegeneration in AD and, reflecting this, higher uptake of TSPO radiotracers such as [ 11 C]PBR28 has been associated with higher Aβ and tau burden, as well as lower MMSE score 14 . PET imaging of cyclooxygenase 1 (COX1) 15 – 17 and P2X ligand-gated ion channel type 7 (P2X7R) 18 – 20 are also being evaluated since both targets have been detected at higher levels in post-mortem brain tissue from AD subjects 21 , with promising imaging agents for both advancing into human studies. These targets enable detection of the change in microglial expression or general neuroinflammation. An alternative approach to imaging neuroinflammation is detection of astrocytosis 22 . There are a number of ways imaging researchers are trying to accomplish this, including targeting imidazoline 2 binding sites (I 2 BS) expressed in the outer mitochondrial membrane of astrocytes, as well as evaluating whether TSPO comes mainly from astrocytes later in the inflammatory cascade 23 . However, the target that has seen the most development for PET imaging in the context of reactive astrocytes is monoamine oxidase B (MAO-B) 24 . MAO-B is a metabolic enzyme that is found on the outer mitochondrial membrane of astrocytes. Its main function is to metabolize endogenous monoamine neurotransmitters such as dopamine and norepinephrine 25 . MAO-B is a particularly attractive imaging target as it exists predominantly in astrocytes, with only a small quantity expressed in serotonergic neurons. This high specificity is beneficial for PET imaging as it gives clear imaging results and enables straightforward data analysis 26 . Since the pioneering work of Fowler and others in the 1980s 27 , several radiotracers have been evaluated for clinical PET imaging of MAO-B, including: [ 11 C/ 18 F]deprenyl as well as their deuterated derivatives 4 , 28 – 32 , [ 11 C]SL2511.88 33–36 , [ 18 F]THK5351 37 , and [ 18 F]SMBT 38 , 39 . A number of these tracers have been used for imaging ADRD, with demonstrated specificity for MAO-B over MAO-A, and discerning differences in healthy control subjects, subjects with mild cognitive impairment (MCI), and later staged AD subjects 28 , 33 , 38 . Studies with [ 11 C]deprenyl have also illuminated longitudinal changes in astrocytosis, Aβ accumulation, and glucose hypometabolism in subjects with autosomal dominant AD 7 , demonstrating that changes in all these parameters can be detected prior to changes in clinical cognition. However, a limitation of all the current radiotracers for MAO-B is that they are based upon inhibitors of the enzyme. As such, while they enable quantitation of the amount and location of MAO-B, they provide no information on its metabolic activity or functional state. The ability to quantify MAO-B activity using PET would allow for further investigation into the metabolic state of the astrocytes in AD brains. This is of interest as astrocytes can exist in various different morphologies, which serve different roles in the brain. 9 For instance, neuroinflammation can be beneficial, such as when it promotes scar tissue formation around damaged areas of the brain following stoke or TBI. 40 Conversely, when it becomes chronic, neuroinflammation is a prolonged and uncontrolled inflammatory response that can become self-propagating and harmful, leading to neuron damage, loss of function, and neurodegeneration, as seen in ADRD 41 . Being able to discern the type of neuroinflammation that is occurring would greatly improve our knowledge of the role these cells play, and this is crucial to understand in the case of leveraging anti-inflammatory agents as a potential ADRD treatment strategy. We hypothesized a substrate-based radiotracer that, following oxidation by MAO-B, results in a labeled trapped metabolite would enable quanitifcation of MAO-B activity, akin to [ 18 F]fluorodeoxyglucose (FDG) or N-[ 11 C]methylpiperidin-4-yl propionate (PMP) for hexokinase-2 and acetylcholinesterase, respectively 42 – 45 . In marked constrast to inhibitor-based imaging agents which provide information on enzyme expression levels, the rate of trapping of a substrate-based tracer reflects enzyme activity. To this end, our group first published in vivo imaging of MAO-B with the radiotracer 4-methyl-7-[(1-[ 11 C]methyl-1,2,3,6-tetrahydropyridin-4-yl)-oxy]-2Hchromen-2-one ([ 11 C]COU, 1 ) in 2015 (Fig. 1 ) 46 . This radiotracer was inspired by the evaluation of MAO-B metabolism using analogues of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) pioneered by the Castagnoli lab 47 , 48 . Castagnoli showed that adding an ether linkage between the phenyl group and the tetrahydropyridine (THP) in the MPTP structure allowed the molecule to be cleaved by the enzyme resulting in two non-toxic metabolites, rather than generating MPP + which becomes trapped in dopaminergic neurons leading to neuronal cell death and Parkinsonian symptoms 48 – 50 . We have previously shown that [ 11 C]COU penetrates the CNS in rodents and nonhuman primates, and that the PET signal in the brain can be reduced by pretreatment with MAO-B inhibitors such as deprenyl. 46 , 49 , 51 [ 11 C]COU is first oxidized by MAO-B to give intermediate 2 , which is subsequently hydrolyzed to generate 1-methyl-2,3-dihydropyridin-4(1H)-one ( 3 ) and coumarin ( 4 ) (Fig. 1 ). The small polar metabolite 3 is trapped in the brain, suggesting that kinetic modeling can be used to quantify MAO-B activity in the future. 42 – 45 In preliminary safety studies, [ 11 C]COU was also shown to be non-toxic by using [ 11 C]DTBZ PET to show that dopaminergic neurons, which are damaged by neurotoxic MPTP, are unaffected by [ 11 C]COU. 46,51,52 Taken together, the promising preclinical imaging studies and favorable safety profile motivated us to translate [ 11 C]COU into the clinic. In order to translate [ 11 C]COU into first-in-human studies, it is required to validate the radiosynthesis according to GMP regulations, and demonstrate in vivo safety through preclinical estimates of radiation absorbed dose (dosimetry) and single species pharmacology/toxicology studies. Completion of these IND-enabling studies is the focus of this report. Results and Discussion Radiochemistry Validation COU precursor and reference standard ([ 12 C] 2 ) standard were synthesized at gram scale using reported procedures (see Supporting Information for details). Both the standard and precursor lots were analyzed by NMR and analytical HPLC annually for purity and repurified when necessary. These compounds were then aliquoted into 1 mg lots and stored in a -20 ℃ freezer with desiccant until use. Both the reference standard and precursor are stable when stored in this fashion, and annual recertification has revealed no appreciable decomposition over at least 5 years. Table 1. The release criteria for [ 11 C]COU as established by USP with the results from the three validation runs and pass (met or exceeded the release criteria)/ fail (did not meet the release criteria) qualification. Release Criteria Dose 1 Dose 2 Dose 3 Pass/Fail Batch Size N/A 80.5 mCi 97.7 mCi 100 mCi Pass Radiochemical Yield (decay corrected) N/A 8.26% 9.37% 10.27% Pass Radiochemical Purity ≥ 90% 99.50% 98.90% 99.18% Pass Total COU Concentration ≤ 1.6 μg/mL 1.0168 μg/mL 0.53 μg/mL 0.43 μg/mL Pass Total Impurity Concentration ≤ 1 μg/mL N/D N/D 0.0739 μg/mL Pass Radioactive Strength ≥ 50 mCi/10 mL 80.5 mCi/10mL 97.7 mCi/10mL 100 mCi/10 mL Pass Specific Activity ≥ 500 Ci/mmol 2132 Ci/mmol 4961 Ci/mmol 6321 Ci/mmol Pass pH 4.5-7.5 5 5 5 Pass Visual Inspection Clear, colorless, no precipitate Pass Pass Pass Pass Radiochemical Identity RRT: 0.9-1.1 1.02 1.019 1.02 Pass Radionuclide Identity 18.4-22.4 min 20.08 min 20.52 min 20.39 min Pass Filter Membrane Integrity ≥ 44 psi 48 psi 47.5 psi 47 psi Pass Bacterial Endotoxin Test < 17.5 EU/mL < 2.00 EU/mL < 2.00 EU/mL < 2.00 EU/mL Pass Residual Solvent Analysis Acetone: ≤ 5000 μg/mL Acetone: 9 μg/mL Acetone: 8 μg/mL Acetone: 9 μg/mL Pass MeCN: ≤ 410 μg/mL MeCN: 5 μg/mL MeCN: 16 μg/mL MeCN: 16 μg/mL Pass DMSO: ≤ 5000 μg/mL DMSO: 15 μg/mL DMSO: 42 μg/mL DMSO: N/D μg/mL Pass Total: ≤ 10,000 μg/mL Total: 29 μg/mL Total: 66 μg/mL Total: 25 μg/mL Pass Sterility Test Complies with USP Pass Pass Pass Pass Dosimetry and Biodistribution To determine the acceptable human dose of radioactivity from [ 11 C]COU, four Sprague Dawley rats (2 male, 2 female) for each of four time points were anesthetized with isoflurane and injected via the femoral vein with 150–500 µCi of [ 11 C]COU 53 . The rats were allowed to recover from the anesthesia and roam freely. These rats were then sacrificed via decapitation at 10-, 20-, 60- and 120-minutes post-injection. Tissues of interest were collected and homogenized. Homogenates were counted using an auto-gamma counter, and the data was used to determine in vivo biodistribution (Fig. 3 ). From the calculated biodistribution, medical internal radiation dose (MIRD) formalism using the OLINDA software was calculated to determine the dosimetry 54 (Table 2 ). Consistent with the short half-life of carbon-11 (20 min), dosimetry burden is estimated to be low (Table 2 ), and organs with metabolic or excretory activity (urinary bladder, small intestine, and kidneys) received the highest dose of radiation. This is to be expected as [ 11 C]COU is thought to clear mainly via urinary excretion, and the bladder wall was estimated to receive the largest dose (0.168 rem/mCi). Applying the guidelines of radioactive drug research committees (RDRCs) operating in the United States, the dose limit for adults is defined as follows: 30 mSv per single injection for the whole body, lens of the eyes, red marrow, and gonads; 50 mSv per year for the whole body, lens of the eyes, red marrow, and gonads; 50 mSv per single injection for all other organs; and 150 mSv per year for all other organs (FDA 21 CFR 361.1). Each organ as well as the whole-body calculation for radiation exposure fell below safety guidelines. The estimated dosimetry for [ 11 C]COU thus allows administration of up to 2 x 18 mCi doses of [ 11 C]COU in future clinical studies with an effective dose of 3.06 mSv, which falls within the acceptable limits established by the RDRC. Table 2 Estimated human equivalent dosimetry for each major tissue as well as whole body dose. Target Organ Gender Averaged Dose (mSv/MBq) Target Organ Gender Averaged Dose (mSv/MBq) Adrenals 2.91E-03 Lungs 1.77E-03 Brain 1.05E-03 Ovaries 3.97E-03 Breasts 2.56E-03 Pancreas 2.65E-03 Esophagus 2.58E-03 Prostate 4.78E-03 Eyes 1.21E-03 Salivary Glands 2.56E-03 Gallbladder Wall 3.55E-03 Red Marrow 2.58E-03 Left colon 3.79E-03 Osteogenic Cells 2.28E-03 Small Intestine 1.26E-02 Spleen 2.24E-03 Stomach Wall 3.23E-03 Testes 1.71E-03 Right colon 5.65E-03 Thymus 2.71E-03 Rectum 5.31E-03 Thyroid 2.60E-03 Heart Wall 1.81E-03 Urinary Bladder Wall 4.52E-02 Kidneys 6.55E-03 Uterus 5.50E-03 Liver 3.43E-03 Total Body 3.20E-03 Effective Dose : 4.60E-03 Pharmacology and Toxicology Studies A single-species pharm-tox study to assess preclinical safety of COU was conducted in Sprague-Dawley rats. Rodents were given either a single injection of 86 µg/kg of COU (100x the anticipated dose for future clinical PET imaging studies) (18 male, 18 female) or 5% ethanol in saline vehicle (4 male, 4 female) and sacrificed either 2-4- or 15-days post-injection to look for acute or sub-acute effects, respectively. Parameters for evaluation included clinical observations, body weights, food intake, and physical examinations, including ophthalmology. Additionally, organ weights were recorded and gross (macroscopic) pathological examinations were performed on all study animals at necropsy. Hematology and clinical chemistry evaluations were performed on blood samples collected from all study animals just prior to necropsy. Histopathological (microscopic) examinations were performed on the tissues collected at necropsy. All measurements taken during this study were within normal limits and no drug-related adverse reactions were reported and no drug-related clinical findings. Body weight stayed steady through the study with a mean weight of 211 g at baseline and 285 g on day 15 for males and 214 g at baseline and 233 g on day 15 for females. This increase follows normal weight gain for rats 55 . Food consumption also stayed consistent with an average of 21.9 ± 1.8 g/day for males and 17.2 ± 1.6 g/day for females. All organs measured weighed similar from day 2–4 to day 15. All blood chemistry measurements and blood cell counts were not significantly changed between days 2–4 and 15. In the animals sacrificed at days 2–4, a low grade intermyelinic edema was observed. In a supplemental study, this was investigated further and since both vehicle- and COU-treated animals had similar brain lesions, it was determined that these lesions were not directly COU related (see Supplementary Information). Instead, the vacuolation in brain appears to be vehicle‐related or to be due to specimen processing. White matter vacuolation is a very common postmortem artifact associated with fixation if there is excessive exposure to alcohol ( https://ntp.niehs.nih.gov/nnl/nervous/brain/index.htm ). The fact that formulated COU and vehicle both contained 5% ethanol USP (v/v), offers a possible explanation for this finding. From this study, COU was determined to have a safety profile appropriate for clinical translation, with a maximum tolerated dose of COU ≥ 86 µg/kg given as a single intravenous injection. This corresponds to the human equivalent dose being ≥ 14 µg/kg. From the toxicology analysis, the effective dose for use in future clinical studies with [ 11 C]COU was set to ≤ 0.14 µg/kg, 100 x below the NOAEL limit estimated from the rodent pharmacology – toxicology studies. MATERIALS AND METHODS Synthesis Validation General Considerations Detailed experimental protocol, including mass spectrometry, nuclear magnetic resonance (NMR) spectra, semi-preparative and analytical high-performance liquid chromatography (HPLC) traces, are provided in the Supporting Information accompanying this article. Large Scale Synthesis of COU Precursor and Standard To aide in clinical translation, the synthesis of COU precursor and standard were modified to gram scale. This was done with optimization of the synthesis reported in Brooks, et. al. 2020 51 . We synthesized 421 mg of precursor at 97% purity and 378 mg of standard using the procedure reported by Brooks, et. el., 2015 46 (see see Supplemental Information for more information). Both the standard and precursor lots were analyzed by NMR and analytical HPLC annually for purity and repurified when necessary. These compounds were then aliquoted into 1 mg lots and stored in a -20 ℃ freezer until use. Radiosynthesis of [ 11 C]COU : Production of 11 C-labeled radiotracers conducted using General Electric (GE) TRACERLab FX C-Pro automated radiochemistry synthesis module. [ 11 C]Carbon dioxide ([ 11 C]CO 2 ) was produced via 14 N(p,α) 11 C nuclear reaction using a GE PET Trace cyclotron (60 µA beam for 30 min) and converted by standard procedures into 11 C-labeled methyl triflate ([ 11 C]CH 3 OTf) from 11 C-labeled methyl iodine ([ 11 C]CH 3 I) (700 mCi for 30 minute beam). COU precursor (1 mg) was dissolved in DMSO (100 µL) and added to TRACERLab reactor. [ 11 C]CH 3 OTf was bubbled through the precursor solution for 3 minutes at room temperature at a rate of 15 mL/min. HPLC buffer (1 mL, 50% MeCN:H 2 O, 50 mM NH 4 HCO 3 , pH 10) was then added to dilute and quench the reaction mixture. The crude reaction mixture was purified using semi-preparative HPLC (column: Gemini 250x10 mm-5µ Luna C18, flow rate: 4 mL/min; 50% MeCN:H 2 O, 50 mM NH 4 HCO 3 , pH 10). The peak corresponding to [ 11 C]COU was collected and reformulated by diluting in 50 mL of water and trapping the product on a C18 1cc solid phase extraction (SPE) cartridge. Following trapping, the SPE cartridge was rinsed with water (5 mL) to remove residual MeCN. [ 11 C]COU was then eluted with ethanol USP (0.5 mL) and diluted with saline USP (9.5 mL) to produce a formulated dose (5% ethanol in saline) that was then filtered through a 0.22 µm sterile filter into a sterile vial. Following terminal sterilization, a sample (0.5 mL) is removed from the batch and submitted for quality control (QC) testing as described below. The process is accomplished in an overall synthesis times of 30 min from end-of-bombardment (EOB). Quality Control All quality control analyses were performed according to requirements described in US Pharmacopeia Chapter and United States Code 21 USC 321. All release criteria are shown with acceptable thresholds along with a pass/fail qualification in Table 1. Analytical HPLC Both chemical and radiochemical purity were determined using a Shimadzu LC2010 HPLC equipped with a Bioscan/Eckert and Ziegler radioactivity and ultraviolet detector (Column: Gemini NX, 5µ, 250 x 4.6 mm, flow rate: 1 mL/min, mobile phase: 50% MeCN:H 2 O, 50 mM NH 4 HCO 3 , pH: 10, t R : 5.75 ± 0.1 min). pH Test The pH of the formulated dose of [ 11 C]COU was analyzed by placing a sample of the dose on a pH indicator strip. The indicator was then compared to the provided reference to determine the pH. Filter Integrity Test The sterile filter attached to the final dose vial was removed from the hot-cell. The filter and needle were then attached to a nitrogen supply with a pressure regulator. The needle was submerged in water and the nitrogen pressure was slowly increased. The pressure is increased until bubbles appear in the water (the bubble point). This pressure is then recorded. Endotoxin Test Endotoxins were measured using a Charles River EndoSafe Portable Testing System. This is performed by adding a small amount of the formulated [ 11 C]COU dose into the reservoir on the PTS cartridge to detect the amount of endotoxins in the sample. Sterility Test Fluid thioglycolate media (FTM) and soybean casein digest agar media (SCDM) culture tubes were utilized for evaluation of the sterility of [ 11 C]COU doses. The culture tubes were inoculated with dose samples then incubated at 20–25℃ (FTM) or 30–35℃ (SCDM) for 14 days alongside both positive and negative controls. The culture tubes were inspected visually at 3-, 8-, and 14-days post-inoculation. Sterility was confirmed based on the visual determination of turbidity in the samples based on both the positive and negative controls. Biodistribution and Dosimetry Male (n = 2) and female (n = 2) Sprague Dawley (SD) rats weighing 161–251 g were anesthetized using isoflurane and subsequently injected with 150–500 µCi of [ 11 C]COU via femoral vein. Pressure was applied to the injection site to stop bleeding. The rats were allowed to recover from the anesthetic and resume normal activity. Each animal was sacrificed by decapitation at either 10, 20, 60, or 120 min post injection. Tissues and fluids were excised, homogenized, and counted for radioactivity in an auto-gamma counter to determine dosimetry and biodistribution. The results were corrected for radioactive decay and expressed in terms of percent-injected dose per gram of tissue (%ID/g) (see Supplemental Information and Supplemental Table 1 for more information). The biodistribution data was used to estimate human internal radiation dosimetry, calculated from rat biodistribution using the MIRD formalism (see Supplemental Information and Table 2 for more information). Pharmacology and Toxicology Studies Pharmacology and Toxicology studies were conducted at the Michigan State University In Vivo facility in Sprague Dawley rats. Rodents were housed individually and given free access to rodent chow and water. Animals were housed individually in plastic solid-bottom cages with aspen bedding throughout the duration of the study. In addition, animals had access to fresh water and were provided standard rodent chow in sufficient amounts to ensure ad libitum consumption. Sprague-Dawley rats were obtained from Charles River Laboratories and after approx. 1 week of acclimation, body weights were recorded [184–335 grams (males) or 200–249 grams (females)] at the time of dosing initiation. Light anesthesia was carried out using isoflurane, and then blood (~ 1 mL total) was collected into K 3 EDTA and serum tubes and was then processed for clinical chemistry and complete blood count (CBC) baseline measurements. The animals were given either a single i.v. injection of 86 µg/kg of COU (100x the expected dose for PET imaging study) (18 male, 18 female) or 5% ethanol in saline vehicle (4 male, 4 female) and sacrificed either 2-4- or 15-days post-injection to look for acute or sub-acute effects, respectively. Throughout the study, food intake was periodically monitored. Additional blood samples were collected just prior to sacrifice for repeat CBC analysis. Following euthanasia, terminal body weights were obtained. Various tissues of interest (i.e. heart, kidneys, liver, and brain) were measured and fixed in 10% neutral-buffered formalin. Slides were prepared, stained with standard Hematoxylin and Eosin, and reviewed by a qualified veterinary pathologist. CONCLUSIONS In this work, the radiosynthesis of [ 11 C]COU has been validated, providing formulated product in acceptable yields, purities, molar activities, and sterility suitable for routine clinical use. Dosimetric studies have determined that, at a dose of 18 mCi, human subjects can receive two doses of [ 11 C]COU without exceeding safe dose limits. From our pharmacology and toxicology studies we concluded that the maximum tolerated dose of COU was ≥ 86 µg/kg in Sprague Dawley rats. Human estimated maximum dose was set to ≥ 14 µg/kg based on the rodent studies, and the set dose for clinical trials is ≤ 0.14 µg/kg, 100-fold below the estimated maximum dose. From these preclinical studies, it can be concluded that [ 11 C]COU is safe for translation into clinical studies. To this end, our lab has recently begun first-in-human studies using [ 11 C]COU under the approval of the US Food and Drug Administration and the Michigan Medicine Institutional Review Board. These clinical studies are ongoing, and will be reported out in due course. ASSOCIATED CONTENT Declarations DEDICATION We dedicate this paper to Prof. George A. Garcia on the occasion of his retirement. Congratulations on an illustrious career in medicinal chemistry, and many thanks for your support of Prof. Scott and the UM PET Program throughout the years. Author Contribution The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. Acknowledgement This work was supported by the NIH [R21NS075553 (M.R.K.); R21AG073686 (P.J.H.S. and K.A.F.)] as well as the University of Michigan (Department of Radiology and SOAR). We also thank Teresa Krieger-Burke, DVM, PhD, Dept of Pharmacology & Toxicology at Michigan State University, for her valuable assistance with the COU pharmacology and toxicology study. Data Availability Data is provided within the manuscript or supplementary information. References 2025 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2025, 21 (4), e70235. https://doi.org/10.1002/alz.70235 . Teipel, S.; Gustafson, D.; Ossenkoppele, R.; Hansson, O.; Babiloni, C.; Wagner, M.; Riedel-Heller, S. G.; Kilimann, I.; Tang, Y. Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention. J. Nucl. Med. 2022, 63 (7), 981–985. https://doi.org/10.2967/jnumed.121.262239 . Cohen, B. M.; Sonntag, K.-C. Identifying the Earliest-Occurring Clinically Targetable Precursors of Late-Onset Alzheimer’s Disease. eBioMedicine 2024, 106 , 105238. https://doi.org/10.1016/j.ebiom.2024.105238 . Carter, S. F.; Schöll, M.; Almkvist, O.; Wall, A.; Engler, H.; Långström, B.; Nordberg, A. Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11 C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11 C-Pittsburgh Compound B and 18 F-FDG. J. Nucl. Med. 2012, 53 (1), 37–46. https://doi.org/10.2967/jnumed.110.087031 . Benzinger, T. L. S.; Blazey, T.; Jack, C. R.; Koeppe, R. A.; Su, Y.; Xiong, C.; Raichle, M. E.; Snyder, A. Z.; Ances, B. M.; Bateman, R. J.; Cairns, N. J.; Fagan, A. M.; Goate, A.; Marcus, D. S.; Aisen, P. S.; Christensen, J. J.; Ercole, L.; Hornbeck, R. C.; Farrar, A. M.; Aldea, P.; Jasielec, M. S.; Owen, C. J.; Xie, X.; Mayeux, R.; Brickman, A.; McDade, E.; Klunk, W.; Mathis, C. A.; Ringman, J.; Thompson, P. M.; Ghetti, B.; Saykin, A. J.; Sperling, R. A.; Johnson, K. A.; Salloway, S.; Correia, S.; Schofield, P. R.; Masters, C. L.; Rowe, C.; Villemagne, V. L.; Martins, R.; Ourselin, S.; Rossor, M. N.; Fox, N. C.; Cash, D. M.; Weiner, M. W.; Holtzman, D. M.; Buckles, V. D.; Moulder, K.; Morris, J. C. Regional Variability of Imaging Biomarkers in Autosomal Dominant Alzheimer’s Disease. Proc. Natl. Acad. Sci. 2013, 110 (47), E4502–E4509. https://doi.org/10.1073/pnas.1317918110 . Villemagne, V. L.; Burnham, S.; Bourgeat, P.; Brown, B.; Ellis, K. A.; Salvado, O.; Szoeke, C.; Macaulay, S. L.; Martins, R.; Maruff, P.; Ames, D.; Rowe, C. C.; Masters, C. L. Amyloid β Deposition, Neurodegeneration, and Cognitive Decline in Sporadic Alzheimer’s Disease: A Prospective Cohort Study. Lancet Neurol. 2013, 12 (4), 357–367. https://doi.org/10.1016/S1474-4422(13)70044-9 . Rodriguez-Vieitez, E.; Saint-Aubert, L.; Carter, S. F.; Almkvist, O.; Farid, K.; Schöll, M.; Chiotis, K.; Thordardottir, S.; Graff, C.; Wall, A.; Långström, B.; Nordberg, A. Diverging Longitudinal Changes in Astrocytosis and Amyloid PET in Autosomal Dominant Alzheimer’s Disease. Brain 2016, 139 (3), 922–936. https://doi.org/10.1093/brain/awv404 . Narayanaswami, V.; Dahl, K.; Bernard-Gauthier, V.; Josephson, L.; Cumming, P.; Vasdev, N. Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO. Mol. Imaging 2018, 17 , 1536012118792317. https://doi.org/10.1177/1536012118792317 . Khakh, B. S.; Sofroniew, M. V. Diversity of Astrocyte Functions and Phenotypes in Neural Circuits. Nat. Neurosci. 2015, 18 (7), 942–952. https://doi.org/10.1038/nn.4043 . Heneka, M. T.; Carson, M. J.; Khoury, J. E.; Landreth, G. E.; Brosseron, F.; Feinstein, D. L.; Jacobs, A. H.; Wyss-Coray, T.; Vitorica, J.; Ransohoff, R. M.; Herrup, K.; Frautschy, S. A.; Finsen, B.; Brown, G. C.; Verkhratsky, A.; Yamanaka, K.; Koistinaho, J.; Latz, E.; Halle, A.; Petzold, G. C.; Town, T.; Morgan, D.; Shinohara, M. L.; Perry, V. H.; Holmes, C.; Bazan, N. G.; Brooks, D. J.; Hunot, S.; Joseph, B.; Deigendesch, N.; Garaschuk, O.; Boddeke, E.; Dinarello, C. A.; Breitner, J. C.; Cole, G. M.; Golenbock, D. T.; Kummer, M. P. Neuroinflammation in Alzheimer’s Disease. Lancet Neurol. 2015, 14 (4), 388–405. https://doi.org/10.1016/S1474-4422(15)70016-5 . Chaney, A. M.; Deal, E. M.; Jackson, I. M.; James, M. L. PET Imaging of Neuroinflammation. In Molecular Imaging ; Elsevier, 2021; pp 1335–1371. Chauveau, F.; Winkeler, A.; Chalon, S.; Boutin, H.; Becker, G. PET Imaging of Neuroinflammation: Any Credible Alternatives to TSPO Yet? Mol. Psychiatry 2025, 30 (1), 213–228. https://doi.org/10.1038/s41380-024-02656-9 . Gouilly, D.; Saint-Aubert, L.; Ribeiro, M.; Salabert, A.; Tauber, C.; Péran, P.; Arlicot, N.; Pariente, J.; Payoux, P. Neuroinflammation PET Imaging of the Translocator Protein (TSPO) in Alzheimer’s Disease: An Update. Eur. J. Neurosci. 2022, 55 (5), 1322–1343. https://doi.org/10.1111/ejn.15613 . Rossano, S. M.; Johnson, A. S.; Smith, A.; Ziaggi, G.; Roetman, A.; Guzman, D.; Okafor, A.; Klein, J.; Tomljanovic, Z.; Stern, Y.; Brickman, A. M.; Lee, S.; Kreisl, W. C.; Lao, P. Microglia Measured by TSPO PET Are Associated with Alzheimer’s Disease Pathology and Mediate Key Steps in a Disease Progression Model. Alzheimers Dement. 2024, 20 (4), 2397–2407. https://doi.org/10.1002/alz.13699 . Kim, M.-J.; Anaya, F. J.; Manly, L. S.; Lee, J.-H.; Hong, J.; Shrestha, S.; Telu, S.; Henry, K.; Santamaria, J. A. M.; Liow, J.-S.; Zanotti-Fregonara, P.; Shetty, H. U.; Zoghbi, S. S.; Pike, V. W.; Innis, R. B. Whole-Body PET Imaging in Humans Shows That 11 C-PS13 Is Selective for Cyclooxygenase-1 and Can Measure the In Vivo Potency of Nonsteroidal Antiinflammatory Drugs. J. Nucl. Med. 2023, 64 (1), 159–164. https://doi.org/10.2967/jnumed.122.264061 . Kenou, B. V.; Manly, L. S.; Rubovits, S. B.; Umeozulu, S. A.; Van Buskirk, M. G.; Zhang, A. S.; Pike, V. W.; Zanotti-Fregonara, P.; Henter, I. D.; Innis, R. B. Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia. J. Nucl. Med. 2022, 63 (Supplement 1), 53S-59S. https://doi.org/10.2967/jnumed.121.263199 . Ghazanfari, N.; Kim, M.-J.; Knoer, C.; Hong, J.; Ahmadi, F.; Montero Stantamaria, J. A.; Zoghbi, S.; Liow, J.-S.; Pike, V.; Innis, R.; Zanotti-Fregonara, P. [11C]PS13 Shows High Specific and Displaceable Binding to COX-1 Enzyme in the Human Brain; Journal of Nuclear Medicine: P498, 2023; Vol. 64. Koole, M.; Schmidt, M. E.; Hijzen, A.; Ravenstijn, P.; Vandermeulen, C.; Van Weehaeghe, D.; Serdons, K.; Celen, S.; Bormans, G.; Ceusters, M.; Zhang, W.; Van Nueten, L.; Kolb, H.; De Hoon, J.; Van Laere, K. 18 F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. J. Nucl. Med. 2019, 60 (5), 683–690. https://doi.org/10.2967/jnumed.118.216747 . Hagens, M. H. J.; Golla, S. S. V.; Janssen, B.; Vugts, D. J.; Beaino, W.; Windhorst, A. D.; O’Brien-Brown, J.; Kassiou, M.; Schuit, R. C.; Schwarte, L. A.; De Vries, H. E.; Killestein, J.; Barkhof, F.; Van Berckel, B. N. M.; Lammertsma, A. A. The P2X7 Receptor Tracer [11C]SMW139 as an in Vivo Marker of Neuroinflammation in Multiple Sclerosis: A First-in Man Study. Eur. J. Nucl. Med. Mol. Imaging 2020, 47 (2), 379–389. https://doi.org/10.1007/s00259-019-04550-x . Brumberg, J.; Aarnio, R.; Forsberg, A.; Marjamäki, P.; Kerstens, V.; Moein, M. M.; Nag, S.; Wahlroos, S.; Kassiou, M.; Windhorst, A. D.; Halldin, C.; Haaparanta-Solin, M.; Fazio, P.; Oikonen, V.; Rinne, J. O.; Varrone, A. Quantification of the Purinergic P2X 7 Receptor with [ 11 C]SMW139 Improves through Correction for Brain-Penetrating Radiometabolites. J. Cereb. Blood Flow Metab. 2023, 43 (2), 258–268. https://doi.org/10.1177/0271678X221126830 . Chen, J.; Collier, T.; Levey, A.; Schuster, D.; Liang, S. Evaluation of P2X& PET Tracer [18F]JNJ-64413739 on Postmortem Alzheimer’s Disease Human Brain Tissue; Journal of Nuclear Medicine: P794, 2023; Vol. 64. Liu, Y.; Jiang, H.; Qin, X.; Tian, M.; Zhang, H. PET Imaging of Reactive Astrocytes in Neurological Disorders. Eur. J. Nucl. Med. Mol. Imaging 2022, 49 (4), 1275–1287. https://doi.org/10.1007/s00259-021-05640-5 . Guilarte, T. R. TSPO in Diverse CNS Pathologies and Psychiatric Disease: A Critical Review and a Way Forward. Pharmacol. Ther. 2019, 194 , 44–58. https://doi.org/10.1016/j.pharmthera.2018.09.003 . Narayanaswami, V.; Drake, L. R.; Brooks, A. F.; Meyer, J. H.; Houle, S.; Kilbourn, M. R.; Scott, P. J. H.; Vasdev, N. Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases. ACS Chem. Neurosci. 2019, 10 (4), 1867–1871. https://doi.org/10.1021/acschemneuro.9b00081 . Segura-Aguilar, J. Dopamine Oxidative Deamination. In Clinical Studies and Therapies in Parkinson’s Disease ; Elsevier, 2021; pp 203–207. https://doi.org/10.1016/B978-0-12-822120-4.00006-X . Westlund, K. N.; Denney, R. M.; Kochersperger, L. M.; Rose, R. M.; Abell, C. W. Distinct Monoamine Oxidase A and B Populations in Primate Brain. Science 1985, 230 (4722), 181–183. https://doi.org/10.1126/science.3875898 . Fowler, J. S.; MacGregor, R. R.; Wolf, A. P.; Arnett, C. D.; Dewey, S. L.; Schlyer, D.; Christman, D.; Logan, J.; Smith, M.; Sachs, H.; Aquilonius, S. M.; Bjurling, P.; Halldin, C.; Hartvig, P.; Leenders, K. L.; Lundqvist, H.; Oreland, L.; Stålnacke, C.-G.; Långström, B. Mapping Human Brain Monoamine Oxidase A and B with 11 C-Labeled Suicide Inactivators and PET. Science 1987, 235 (4787), 481–485. https://doi.org/10.1126/science.3099392 . Macgregor, R. R.; Fowler, J. S.; Wolf, A. P.; Halldin, C.; Langström, B. Synthesis of Suicide Inhibitors of Monoamine Oxidase: Carbon-11 Labeled Clorgyline, L-Deprenyl and D-Deprenyl. J. Label. Compd. Radiopharm. 1988, 25 (1), 1–9. https://doi.org/10.1002/jlcr.2580250102 . Fowler, J. S.; Wang, G.-J.; Logan, J.; Xie, S.; Volkow, N. D.; MacGregor, R. R.; Schlyer, D. J.; Pappas, N.; Alexoff, D. L.; Patlak, C.; Wolf, A. P. Selective Reduction of Radiotracer Trapping by Deuterium Substitution: Comparison of Carbon-11-L-Deprenyl and Carbon-11-Deprenyl-D2 for MAo-B Mapping. J. Nucl. Med. 1995, 36 (7), 1255–1262. Fowler, J. S.; Wolf, A. P.; MacGregor, R. R.; Dewey, S. L.; Logan, J.; Schlyer, D. J.; Langstrom, B. Mechanistic Positron Emission Tomography Studies: Demonstration of a Deuterium Isotope Effect in the Monoamine Oxidase-Catalyzed Binding of [ 11 C]l‐Deprenyl in Living Baboon Brain. J. Neurochem. 1988, 51 (5), 1524–1534. https://doi.org/10.1111/j.1471-4159.1988.tb01121.x . Arnett, C. D.; Fowler, J. S.; MacGregor, R. R.; Schlyer, D. J.; Wolf, A. P.; Långström, B.; Halldin, C. Turnover of Brain Monoamine Oxidase Measured In Vivo by Positron Emission Tomography Using l -[ 11 C]Deprenyl. J. Neurochem. 1987, 49 (2), 522–527. https://doi.org/10.1111/j.1471-4159.1987.tb02895.x . Ballweg, A.; Klaus, C.; Vogler, L.; Katzdobler, S.; Wind, K.; Zatcepin, A.; Ziegler, S. I.; Secgin, B.; Eckenweber, F.; Bohr, B.; Bernhardt, A.; Fietzek, U.; Rauchmann, B.-S.; Stoecklein, S.; Quach, S.; Beyer, L.; Scheifele, M.; Simmet, M.; Joseph, E.; Lindner, S.; Berg, I.; Koglin, N.; Mueller, A.; Stephens, A. W.; Bartenstein, P.; Tonn, J. C.; Albert, N. L.; Kümpfel, T.; Kerschensteiner, M.; Perneczky, R.; Levin, J.; Paeger, L.; Herms, J.; Brendel, M. [18F]F-DED PET Imaging of Reactive Astrogliosis in Neurodegenerative Diseases: Preclinical Proof of Concept and First-in-Human Data. J. Neuroinflammation 2023, 20 (1), 68. https://doi.org/10.1186/s12974-023-02749-2 . Rusjan, P. M.; Wilson, A. A.; Miler, L.; Fan, I.; Mizrahi, R.; Houle, S.; Vasdev, N.; Meyer, J. H. Kinetic Modeling of the Monoamine Oxidase B Radioligand [11C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography. J. Cereb. Blood Flow Metab. 2014, 34 (5), 883–889. https://doi.org/10.1038/jcbfm.2014.34 . Braga, J.; Kuik, E. J. Y.; Lepra, M.; Rusjan, P. M.; Kish, S. J.; Vieira, E. L.; Nasser, Z.; Verhoeff, N.; Vasdev, N.; Chao, T.; Bagby, M.; Boileau, I.; Kloiber, S.; Husain, M. I.; Kolla, N.; Koshimori, Y.; Faiz, K.; Wang, W.; Meyer, J. H. Astrogliosis Marker [11C]SL25.1188 After COVID-19 With Ongoing Depressive and Cognitive Symptoms. Biol. Psychiatry 2024, S0006322324016561. https://doi.org/10.1016/j.biopsych.2024.09.027 . Gill, T.; Watling, S. E.; Richardson, J. D.; McCluskey, T.; Tong, J.; Meyer, J. H.; Warsh, J.; Jetly, R.; Hutchison, M. G.; Rhind, S. G.; Houle, S.; Vasdev, N.; Kish, S. J.; Boileau, I. Imaging of Astrocytes in Posttraumatic Stress Disorder: A PET Study with the Monoamine Oxidase B Radioligand [11C]SL25.1188. Eur. Neuropsychopharmacol. 2022, 54 , 54–61. https://doi.org/10.1016/j.euroneuro.2021.10.006 . Koshimori, Y.; Cusimano, M. D.; Vieira, E. L.; Rusjan, P. M.; Kish, S. J.; Vasdev, N.; Moriguchi, S.; Boileau, I.; Chao, T.; Nasser, Z.; Ishrat Husain, M.; Faiz, K.; Braga, J.; Meyer, J. H. Astrogliosis Marker 11C-SL25.1188 PET in Traumatic Brain Injury with Persistent Symptoms. Brain 2023, 146 (11), 4469–4475. https://doi.org/10.1093/brain/awad279 . Ishibashi, K. Clinical Application of MAO-B PET Using 18 F‐THK5351 in Neurological Disorders. Geriatr. Gerontol. Int. 2024, 24 (S1), 31–43. https://doi.org/10.1111/ggi.14729 . Villemagne, V. L.; Harada, R.; Doré, V.; Furumoto, S.; Mulligan, R.; Kudo, Y.; Burnham, S.; Krishnadas, N.; Bozinovski, S.; Huang, K.; Lopresti, B. J.; Yanai, K.; Rowe, C. C.; Okamura, N. First-in-Humans Evaluation of 18 F-SMBT-1, a Novel 18 F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis. J. Nucl. Med. 2022, 63 (10), 1551–1559. https://doi.org/10.2967/jnumed.121.263254 . Villemagne, V. L.; Harada, R.; Doré, V.; Furumoto, S.; Mulligan, R.; Kudo, Y.; Burnham, S.; Krishnadas, N.; Bourgeat, P.; Xia, Y.; Laws, S.; Bozinovski, S.; Huang, K.; Ikonomovic, M. D.; Fripp, J.; Yanai, K.; Okamura, N.; Rowe, C. C. Assessing Reactive Astrogliosis with 18F-SMBT-1 Across the Alzheimer Disease Spectrum. J. Nucl. Med. 2022, 63 (10), 1560–1569. https://doi.org/10.2967/jnumed.121.263255 . Linnerbauer, M.; Rothhammer, V. Protective Functions of Reactive Astrocytes Following Central Nervous System Insult. Front. Immunol. 2020, 11 , 573256. https://doi.org/10.3389/fimmu.2020.573256 . Zhang, W.; Xiao, D.; Mao, Q.; Xia, H. Role of Neuroinflammation in Neurodegeneration Development. Signal Transduct. Target. Ther. 2023, 8 (1), 267. https://doi.org/10.1038/s41392-023-01486-5 . Kuhl, D. E.; Koeppe, R. A.; Minoshima, S.; Snyder, S. E.; Ficaro, E. P.; Foster, N. L.; Frey, K. A.; Kilbourn, M. R. In Vivo Mapping of Cerebral Acetylcholinesterase Activity in Aging and Alzheimer’s Disease. Neurology 1999, 52 (4), 691–691. https://doi.org/10.1212/WNL.52.4.691 . Kilbourn, M. R.; Snyder, S. E.; Sherman, P. S.; Kuhl, D. E. In Vivo Studies of Acetylcholinesterase Activity Using a Labeled Substrate,N-[11C]Methylpiperdin-4-Yl Propionate ([11C]PMP). Synapse 1996, 22 (2), 123–131. https://doi.org/10.1002/(SICI)1098-2396 (199602)22:2%253C123::AID-SYN5%253E3.0.CO;2-F. Minoshima, S.; Cross, D.; Thientunyakit, T.; Foster, N. L.; Drzezga, A. 18 F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies. J. Nucl. Med. 2022, 63 (Supplement 1), 2S-12S. https://doi.org/10.2967/jnumed.121.263194 . Research, C. for D. E. and. Review of F-18 Fluoro-2-Deoxyglucose (F-18 FDG) Positron Emission Tomography in the Evaluation of Malignancy - August 4, 1999. FDA 2018. Brooks, A. F.; Shao, X.; Quesada, C. A.; Sherman, P.; Scott, P. J. H.; Kilbourn, M. R. In Vivo Metabolic Trapping Radiotracers for Imaging Monoamine Oxidase-A and -B Enzymatic Activity. ACS Chem. Neurosci. 2015, 6 (12), 1965–1971. https://doi.org/10.1021/acschemneuro.5b00223 . Franot, C.; Mabic, S.; Castagnol Jr, N. Chemical Model Studies on the Monoamine Oxidase-B Catalyzed Oxidation of 4-Substituted 1-Cyclopropyl-1,2,3,6-Tetrahydropyridines. Bioorg. Med. Chem. 1998, 6 (3), 283–291. https://doi.org/10.1016/S0968-0896(97)10033-5 . Bissel, P.; Bigley, M. C.; Castagnoli, K.; Castagnoli Jr, N. Synthesis and Biological Evaluation of MAO-A Selective 1,4-Disubstituted-1,2,3,6-Tetrahydropyridinyl Substrates. Bioorg. Med. Chem. 2002, 10 (9), 3031–3041. https://doi.org/10.1016/S0968-0896(02)00136-0 . Drake, L. R.; Brooks, A. F.; Mufarreh, A. J.; Pham, J. M.; Koeppe, R. A.; Shao, X.; Scott, P. J. H.; Kilbourn, M. R. Deuterium Kinetic Isotope Effect Studies of a Potential in Vivo Metabolic Trapping Agent for Monoamine Oxidase B. ACS Chem. Neurosci. 2018, 9 (12), 3024–3027. https://doi.org/10.1021/acschemneuro.8b00219 . Langston, J. W. The MPTP Story. J. Park. Dis. 2024, 7 (Suppl 1), S11–S19. https://doi.org/10.3233/JPD-179006 . Brooks, A. F.; Mufarreh, A. J.; Shao, X.; Kaur, T.; Stauff, J.; Arteaga, J.; Kilbourn, M. R.; Scott, P. J. H. Improved Synthesis of [11C]COU and [11C]PHXY, Evaluation of Neurotoxicity, and Imaging of MAOs in Rodent Heart. ACS Med. Chem. Lett. 2020, 11 (11), 2300–2304. https://doi.org/10.1021/acsmedchemlett.0c00419 . Brooks, A. F.; Drake, L. R.; Shao, X.; Zhao, A.; Scott, P. J. H.; Kilbourn, M. R. Evaluation of Enzyme Substrate Radiotracers as PET/MRS Hybrid Imaging Agents. ACS Med. Chem. Lett. 2018, 9 (11), 1140–1143. https://doi.org/10.1021/acsmedchemlett.8b00402 . Stabin, M. G.; Siegel, J. A. Physical Models and Dose Factors for Use in Internal Dose Assessment. Health Phys. 2003, 85 (3), 294–310. Stabin, M. G. OLINDA/EXM 2—The Next-Generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine. Health Phys. 2023, 124 (5), 397. https://doi.org/10.1097/HP.0000000000001682 . Alemáan, C. L.; Más, R. M.; Rodeiro, I.; Noa, M.; Hernández, C.; Menéndez, R.; Gámez, R. Reference Database of the Main Physiological Parameters in Sprague-Dawley Rats from 6 to 32 Months. Lab. Anim. 1998, 32 (4), 457–466. https://doi.org/10.1258/002367798780599802 . Additional Declarations No competing interests reported. Supplementary Files COUPreclinicalSIFinal.pdf Cite Share Download PDF Status: Published Journal Publication published 05 Nov, 2025 Read the published version in Medicinal Chemistry Research → Version 1 posted Editorial decision: Revision requested 06 Oct, 2025 Editor assigned by journal 06 Oct, 2025 Submission checks completed at journal 05 Oct, 2025 First submitted to journal 01 Oct, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7762445","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":525440853,"identity":"59358e7a-ccbd-423b-8c95-fbc644831e65","order_by":0,"name":"Madison Frazier","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Madison","middleName":"","lastName":"Frazier","suffix":""},{"id":525440854,"identity":"c1e875c4-86d7-4de8-b4a3-465100d361d5","order_by":1,"name":"Tanpreet Kaur","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Tanpreet","middleName":"","lastName":"Kaur","suffix":""},{"id":525440855,"identity":"50868f90-cdfb-4093-83aa-481313887edb","order_by":2,"name":"Jenelle Stauff","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Jenelle","middleName":"","lastName":"Stauff","suffix":""},{"id":525440856,"identity":"b63c864d-17f2-4fbb-abdb-0cbde92a84e5","order_by":3,"name":"Wade P. Winton","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Wade","middleName":"P.","lastName":"Winton","suffix":""},{"id":525440857,"identity":"de172dba-5203-486f-9e9e-0b5f1f8e6362","order_by":4,"name":"Bradford D. Henderson","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Bradford","middleName":"D.","lastName":"Henderson","suffix":""},{"id":525440858,"identity":"7e626f8e-6e5c-412e-bc91-17e1512d31b5","order_by":5,"name":"Alexandra S. Dumond","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Alexandra","middleName":"S.","lastName":"Dumond","suffix":""},{"id":525440859,"identity":"e77670c4-c9c5-49b9-aec1-f7d9c544c0d8","order_by":6,"name":"Xia Shao","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Xia","middleName":"","lastName":"Shao","suffix":""},{"id":525440860,"identity":"cc666ba5-c4db-4db9-bb34-9a8b0fda53be","order_by":7,"name":"David M. Raffel","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"David","middleName":"M.","lastName":"Raffel","suffix":""},{"id":525440861,"identity":"40aaba83-c306-4146-954a-199c0e86e786","order_by":8,"name":"Kirk A. Frey","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Kirk","middleName":"A.","lastName":"Frey","suffix":""},{"id":525440862,"identity":"8dd0f5cf-05bd-4865-8ebd-e27d0faa0510","order_by":9,"name":"Michael R. Kilbourn","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Michael","middleName":"R.","lastName":"Kilbourn","suffix":""},{"id":525440863,"identity":"2ad9513d-657c-44ef-80d6-9d351fb83891","order_by":10,"name":"Allen F. Brooks","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Allen","middleName":"F.","lastName":"Brooks","suffix":""},{"id":525440864,"identity":"b4c668ed-2e39-4dde-b622-3b45e13e8f6b","order_by":11,"name":"Peter J. H. Scott","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAxElEQVRIiWNgGAWjYFCCMxCKH4gPMDaASOK0GEhINhCvhQeixQCkkigt5oxnD3/4UfGnzvhGduKBnzsY5PhuJODXYtlwLk2y54yBhNmN3A0He88wGEsS0mJw4IwZM2MbRMthxjaGxA1EaDH+DNJiPAOipZ4YLQbSIC0GEhAtCQaE/XLGDOgXY8kZZ94C/dImYTjzzAP8WswlzhgDQ0yOn789d/OHn2028nzHCTlM4gAKXwK/crAW/gbCikbBKBgFo2CEAwBMck0wPTKkOwAAAABJRU5ErkJggg==","orcid":"","institution":"University of Michigan","correspondingAuthor":true,"prefix":"","firstName":"Peter","middleName":"J. H.","lastName":"Scott","suffix":""}],"badges":[],"createdAt":"2025-10-01 21:23:12","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7762445/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7762445/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s00044-025-03496-0","type":"published","date":"2025-11-05T15:57:19+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":94236857,"identity":"ae81ead2-6a4b-4eae-b154-6716e198d37b","added_by":"auto","created_at":"2025-10-24 02:16:43","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":14855,"visible":true,"origin":"","legend":"\u003cp\u003eProposed mechanism of trapping for [\u003csup\u003e11\u003c/sup\u003eC]COU.\u003c/p\u003e","description":"","filename":"Picture1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7762445/v1/49d8508b7deb9c086ed896f6.jpg"},{"id":94236859,"identity":"fd230db4-092a-46ab-8105-55fa59b75348","added_by":"auto","created_at":"2025-10-24 02:16:43","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":10784,"visible":true,"origin":"","legend":"\u003cp\u003eSynthesis of [\u003csup\u003e11\u003c/sup\u003eC]COU (\u003cstrong\u003e1\u003c/strong\u003e) via [\u003csup\u003e11\u003c/sup\u003eC]methylation of free amine COU precursor. Synthesis performed on GE TracerLab FX\u003csub\u003ec-pro\u003c/sub\u003e platform.\u003c/p\u003e","description":"","filename":"Picture2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7762445/v1/2d98eff36248e842252ec4b4.jpg"},{"id":94236860,"identity":"8f8d301f-e69e-4418-8b8a-643ab059501b","added_by":"auto","created_at":"2025-10-24 02:16:44","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":239321,"visible":true,"origin":"","legend":"\u003cp\u003eEstimated human equivalent dosimetry for each major tissue as well as whole body dose.\u003c/p\u003e","description":"","filename":"Picture3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7762445/v1/78e28225f4e86464ab73da28.jpg"},{"id":95564136,"identity":"977cae0c-8369-4be9-80c3-42612c25897e","added_by":"auto","created_at":"2025-11-10 16:08:14","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1178283,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7762445/v1/cd1ab3cc-393d-418c-96c4-5880537b92d6.pdf"},{"id":94236861,"identity":"44d0cf33-71d1-4310-80ac-67426facd4d4","added_by":"auto","created_at":"2025-10-24 02:16:44","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":3720769,"visible":true,"origin":"","legend":"","description":"","filename":"COUPreclinicalSIFinal.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7762445/v1/5374975c68400968955acc6d.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"IND-Enabling Preclinical Studies of [11C]COU, a Trapped Metabolite PET Radiotracer for Monoamine Oxidase-B","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eAs the global population ages, the incidence of Alzheimer\u0026rsquo;s Disease and related dementias (ADRD) is expected to increase, thus the need for earlier clinical diagnosis is essential\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. The current standard of care involves measuring amyloid β (Aβ) plaques and tau neurofibrillary tangles (NFTs) either through blood tests or Positron Emission Tomography (PET) imaging\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. Treatments to alleviate Aβ burden, lecanemab and donanemab, are effective at removing plaques from the brain and have recently received FDA approval for treatment of AD. However, when Aβ and tau accumulation become measurable, neuronal impairment and loss has already begun and thus alleviation of symptoms with these treatments is somewhat limited, yet disease progression has been slowed with the use of these new drugs.\u003c/p\u003e\u003cp\u003eThe process of plaque deposition and NFT formation have been shown to begin years before symptoms arise in ADRD\u003csup\u003e\u003cspan additionalcitationids=\"CR4 CR5 CR6\" citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. Due to this disconnect in disease onset and diagnosis, many researchers have begun to look for other biomarkers that can be detected earlier in AD progression. Currently the earliest detectable change in patients who will go on to develop AD is neuroinflammation\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e,\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e. There are two cells that play a role in this process, microglia and astrocytes\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. Normally these cells maintain the homeostasis of the neurological system by keeping ions in balance, metabolizing neurotransmitters, and maintaining the blood-brain barrier (BBB)\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. However, as Aβ fibrils begin to build up in the brain, these cells become hyperactivated in a process called gliosis or astrocytosis\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. As neuroinflammation emerges as an early biomarker of ADRD, and modulating immune responses is considered as a potential therapeutic strategy, there is growing interest in quantifying neuroinflammation in ADRD via PET imaging.\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e,\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e Several approaches have used PET to detect activated microglia. For example, the translocator protein 18 kDa (TSPO), expressed on activated microglia, has been widely used for the quantification of neuroinflammation in AD\u003csup\u003e13\u003c/sup\u003e. Evidence suggests microglial activation precedes regional tau and neurodegeneration in AD and, reflecting this, higher uptake of TSPO radiotracers such as [\u003csup\u003e11\u003c/sup\u003eC]PBR28 has been associated with higher Aβ and tau burden, as well as lower MMSE score\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. PET imaging of cyclooxygenase 1 (COX1)\u003csup\u003e\u003cspan additionalcitationids=\"CR16\" citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e and P2X ligand-gated ion channel type 7 (P2X7R)\u003csup\u003e\u003cspan additionalcitationids=\"CR19\" citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e are also being evaluated since both targets have been detected at higher levels in post-mortem brain tissue from AD subjects\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e, with promising imaging agents for both advancing into human studies. These targets enable detection of the change in microglial expression or general neuroinflammation.\u003c/p\u003e\u003cp\u003eAn alternative approach to imaging neuroinflammation is detection of astrocytosis\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. There are a number of ways imaging researchers are trying to accomplish this, including targeting imidazoline\u003csub\u003e2\u003c/sub\u003e binding sites (I\u003csub\u003e2\u003c/sub\u003eBS) expressed in the outer mitochondrial membrane of astrocytes, as well as evaluating whether TSPO comes mainly from astrocytes later in the inflammatory cascade\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. However, the target that has seen the most development for PET imaging in the context of reactive astrocytes is monoamine oxidase B (MAO-B)\u003csup\u003e24\u003c/sup\u003e. MAO-B is a metabolic enzyme that is found on the outer mitochondrial membrane of astrocytes. Its main function is to metabolize endogenous monoamine neurotransmitters such as dopamine and norepinephrine\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e. MAO-B is a particularly attractive imaging target as it exists predominantly in astrocytes, with only a small quantity expressed in serotonergic neurons. This high specificity is beneficial for PET imaging as it gives clear imaging results and enables straightforward data analysis\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e. Since the pioneering work of Fowler and others in the 1980s\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e, several radiotracers have been evaluated for clinical PET imaging of MAO-B, including: [\u003csup\u003e11\u003c/sup\u003eC/\u003csup\u003e18\u003c/sup\u003eF]deprenyl as well as their deuterated derivatives\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan additionalcitationids=\"CR29 CR30 CR31\" citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e, [\u003csup\u003e11\u003c/sup\u003eC]SL2511.88\u003csup\u003e33\u0026ndash;36\u003c/sup\u003e, [\u003csup\u003e18\u003c/sup\u003eF]THK5351\u003csup\u003e37\u003c/sup\u003e, and [\u003csup\u003e18\u003c/sup\u003eF]SMBT\u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e,\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e. A number of these tracers have been used for imaging ADRD, with demonstrated specificity for MAO-B over MAO-A, and discerning differences in healthy control subjects, subjects with mild cognitive impairment (MCI), and later staged AD subjects\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e,\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e. Studies with [\u003csup\u003e11\u003c/sup\u003eC]deprenyl have also illuminated longitudinal changes in astrocytosis, Aβ accumulation, and glucose hypometabolism in subjects with autosomal dominant AD\u003csup\u003e7\u003c/sup\u003e, demonstrating that changes in all these parameters can be detected prior to changes in clinical cognition. However, a limitation of all the current radiotracers for MAO-B is that they are based upon inhibitors of the enzyme. As such, while they enable quantitation of the amount and location of MAO-B, they provide no information on its metabolic activity or functional state.\u003c/p\u003e\u003cp\u003eThe ability to quantify MAO-B activity using PET would allow for further investigation into the metabolic state of the astrocytes in AD brains. This is of interest as astrocytes can exist in various different morphologies, which serve different roles in the brain.\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e For instance, neuroinflammation can be beneficial, such as when it promotes scar tissue formation around damaged areas of the brain following stoke or TBI.\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e Conversely, when it becomes chronic, neuroinflammation is a prolonged and uncontrolled inflammatory response that can become self-propagating and harmful, leading to neuron damage, loss of function, and neurodegeneration, as seen in ADRD\u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u003c/sup\u003e. Being able to discern the type of neuroinflammation that is occurring would greatly improve our knowledge of the role these cells play, and this is crucial to understand in the case of leveraging anti-inflammatory agents as a potential ADRD treatment strategy.\u003c/p\u003e\u003cp\u003eWe hypothesized a substrate-based radiotracer that, following oxidation by MAO-B, results in a labeled trapped metabolite would enable quanitifcation of MAO-B activity, akin to [\u003csup\u003e18\u003c/sup\u003eF]fluorodeoxyglucose (FDG) or N-[\u003csup\u003e11\u003c/sup\u003eC]methylpiperidin-4-yl propionate (PMP) for hexokinase-2 and acetylcholinesterase, respectively\u003csup\u003e\u003cspan additionalcitationids=\"CR43 CR44\" citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e. In marked constrast to inhibitor-based imaging agents which provide information on enzyme expression levels, the rate of trapping of a substrate-based tracer reflects enzyme activity. To this end, our group first published \u003cem\u003ein vivo\u003c/em\u003e imaging of MAO-B with the radiotracer 4-methyl-7-[(1-[\u003csup\u003e11\u003c/sup\u003eC]methyl-1,2,3,6-tetrahydropyridin-4-yl)-oxy]-2Hchromen-2-one ([\u003csup\u003e11\u003c/sup\u003eC]COU, \u003cb\u003e1\u003c/b\u003e) in 2015 (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e)\u003csup\u003e\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e. This radiotracer was inspired by the evaluation of MAO-B metabolism using analogues of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) pioneered by the Castagnoli lab\u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e,\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u003c/sup\u003e. Castagnoli showed that adding an ether linkage between the phenyl group and the tetrahydropyridine (THP) in the MPTP structure allowed the molecule to be cleaved by the enzyme resulting in two non-toxic metabolites, rather than generating MPP\u003csup\u003e+\u003c/sup\u003e which becomes trapped in dopaminergic neurons leading to neuronal cell death and Parkinsonian symptoms\u003csup\u003e\u003cspan additionalcitationids=\"CR49\" citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eWe have previously shown that [\u003csup\u003e11\u003c/sup\u003eC]COU penetrates the CNS in rodents and nonhuman primates, and that the PET signal in the brain can be reduced by pretreatment with MAO-B inhibitors such as deprenyl.\u003csup\u003e\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e,\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e,\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e [\u003csup\u003e11\u003c/sup\u003eC]COU is first oxidized by MAO-B to give intermediate \u003cb\u003e2\u003c/b\u003e, which is subsequently hydrolyzed to generate 1-methyl-2,3-dihydropyridin-4(1H)-one (\u003cb\u003e3\u003c/b\u003e) and coumarin (\u003cb\u003e4\u003c/b\u003e) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). The small polar metabolite \u003cb\u003e3\u003c/b\u003e is trapped in the brain, suggesting that kinetic modeling can be used to quantify MAO-B activity in the future.\u003csup\u003e\u003cspan additionalcitationids=\"CR43 CR44\" citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e In preliminary safety studies, [\u003csup\u003e11\u003c/sup\u003eC]COU was also shown to be non-toxic by using [\u003csup\u003e11\u003c/sup\u003eC]DTBZ PET to show that dopaminergic neurons, which are damaged by neurotoxic MPTP, are unaffected by [\u003csup\u003e11\u003c/sup\u003eC]COU. \u003csup\u003e46,51,52\u003c/sup\u003e Taken together, the promising preclinical imaging studies and favorable safety profile motivated us to translate [\u003csup\u003e11\u003c/sup\u003eC]COU into the clinic. In order to translate [\u003csup\u003e11\u003c/sup\u003eC]COU into first-in-human studies, it is required to validate the radiosynthesis according to GMP regulations, and demonstrate \u003cem\u003ein vivo\u003c/em\u003e safety through preclinical estimates of radiation absorbed dose (dosimetry) and single species pharmacology/toxicology studies. Completion of these IND-enabling studies is the focus of this report.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e"},{"header":"Results and Discussion","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003eRadiochemistry Validation\u003c/h2\u003e\u003cp\u003eCOU precursor and reference standard ([\u003csup\u003e12\u003c/sup\u003eC]\u003cb\u003e2\u003c/b\u003e) standard were synthesized at gram scale using reported procedures (see Supporting Information for details). Both the standard and precursor lots were analyzed by NMR and analytical HPLC annually for purity and repurified when necessary. These compounds were then aliquoted into 1 mg lots and stored in a -20 ℃ freezer with desiccant until use. Both the reference standard and precursor are stable when stored in this fashion, and annual recertification has revealed no appreciable decomposition over at least 5 years.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eTable 1.\u0026nbsp;\u003c/strong\u003eThe release criteria for [\u003csup\u003e11\u003c/sup\u003eC]COU as established by USP \u0026lt;823\u0026gt; with the results from the three validation runs and pass (met or exceeded the release criteria)/ fail (did not meet the release criteria) qualification.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"608\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eRelease Criteria\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eDose 1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eDose 2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eDose 3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass/Fail\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eBatch Size\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eN/A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e80.5 mCi\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e97.7 mCi\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e100 mCi\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eRadiochemical Yield (decay corrected)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eN/A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e8.26%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e9.37%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e10.27%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eRadiochemical Purity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003e\u0026ge; 90%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e99.50%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e98.90%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e99.18%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eTotal COU Concentration\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003e\u0026le; 1.6 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e1.0168 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e0.53 \u0026nbsp;\u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e0.43 \u0026nbsp;\u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eTotal Impurity Concentration\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003e\u0026le; 1 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eN/D\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eN/D\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e0.0739 \u0026nbsp;\u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eRadioactive Strength\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003e\u0026ge; 50 mCi/10 mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e80.5 mCi/10mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e97.7 mCi/10mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e100 mCi/10 mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eSpecific Activity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003e\u0026ge; 500 Ci/mmol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e2132 Ci/mmol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e4961 Ci/mmol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e6321 Ci/mmol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003epH\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003e4.5-7.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eVisual Inspection\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eClear, colorless, no precipitate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eRadiochemical Identity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eRRT: 0.9-1.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e1.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e1.019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e1.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eRadionuclide Identity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003e18.4-22.4 min\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e20.08 min\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e20.52 min\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e20.39 min\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eFilter Membrane Integrity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003e\u0026ge; 44 psi\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e48 psi\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e47.5 psi\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e47 psi\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eBacterial Endotoxin Test\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003e\u0026lt; 17.5 EU/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e\u0026lt; 2.00 EU/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e\u0026lt; 2.00 EU/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003e\u0026lt; 2.00 EU/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" style=\"width: 110px;\"\u003e\n \u003cp\u003eResidual Solvent Analysis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAcetone: \u0026le; 5000 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eAcetone: 9 \u0026nbsp;\u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eAcetone: 8 \u0026nbsp;\u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eAcetone: 9 \u0026nbsp;\u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eMeCN: \u0026le; 410 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eMeCN: 5 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eMeCN: 16 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eMeCN: 16 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eDMSO: \u0026le; 5000 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eDMSO: 15 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eDMSO: 42 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eDMSO: N/D \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eTotal: \u0026le; 10,000 \u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eTotal: 29 \u0026nbsp;\u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eTotal: 66 \u0026nbsp;\u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003eTotal: 25 \u0026nbsp;\u0026mu;g/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 110px;\"\u003e\n \u003cp\u003eSterility Test\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eComplies with USP\u0026lt;71\u0026gt;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 101px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 77px;\"\u003e\n \u003cp\u003ePass\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\u003c/div\u003e\n\u003ch3\u003eDosimetry and Biodistribution\u003c/h3\u003e\n\u003cp\u003eTo determine the acceptable human dose of radioactivity from [\u003csup\u003e11\u003c/sup\u003eC]COU, four Sprague Dawley rats (2 male, 2 female) for each of four time points were anesthetized with isoflurane and injected via the femoral vein with 150\u0026ndash;500 \u0026micro;Ci of [\u003csup\u003e11\u003c/sup\u003eC]COU\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e. The rats were allowed to recover from the anesthesia and roam freely. These rats were then sacrificed via decapitation at 10-, 20-, 60- and 120-minutes post-injection. Tissues of interest were collected and homogenized. Homogenates were counted using an auto-gamma counter, and the data was used to determine in vivo biodistribution (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eFrom the calculated biodistribution, medical internal radiation dose (MIRD) formalism using the OLINDA software was calculated to determine the dosimetry\u003csup\u003e\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e\u003c/sup\u003e (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e2\u003c/span\u003e). Consistent with the short half-life of carbon-11 (20 min), dosimetry burden is estimated to be low (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e2\u003c/span\u003e), and organs with metabolic or excretory activity (urinary bladder, small intestine, and kidneys) received the highest dose of radiation. This is to be expected as [\u003csup\u003e11\u003c/sup\u003eC]COU is thought to clear mainly via urinary excretion, and the bladder wall was estimated to receive the largest dose (0.168 rem/mCi). Applying the guidelines of radioactive drug research committees (RDRCs) operating in the United States, the dose limit for adults is defined as follows: 30 mSv per single injection for the whole body, lens of the eyes, red marrow, and gonads; 50 mSv per year for the whole body, lens of the eyes, red marrow, and gonads; 50 mSv per single injection for all other organs; and 150 mSv per year for all other organs (FDA 21 CFR 361.1). Each organ as well as the whole-body calculation for radiation exposure fell below safety guidelines. The estimated dosimetry for [\u003csup\u003e11\u003c/sup\u003eC]COU thus allows administration of up to 2 x 18 mCi doses of [\u003csup\u003e11\u003c/sup\u003eC]COU in future clinical studies with an effective dose of 3.06 mSv, which falls within the acceptable limits established by the RDRC.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eEstimated human equivalent dosimetry for each major tissue as well as whole body dose.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eTarget Organ\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGender Averaged Dose (mSv/MBq)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eTarget Organ\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eGender Averaged Dose (mSv/MBq)\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eAdrenals\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e2.91E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eLungs\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e1.77E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eBrain\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1.05E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eOvaries\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e3.97E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eBreasts\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e2.56E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003ePancreas\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2.65E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eEsophagus\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e2.58E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eProstate\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e4.78E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eEyes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1.21E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eSalivary Glands\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2.56E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eGallbladder Wall\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e3.55E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eRed Marrow\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2.58E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLeft colon\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e3.79E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eOsteogenic Cells\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2.28E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSmall Intestine\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1.26E-02\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eSpleen\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2.24E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eStomach Wall\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e3.23E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eTestes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e1.71E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eRight colon\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e5.65E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eThymus\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2.71E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eRectum\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e5.31E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eThyroid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2.60E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eHeart Wall\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1.81E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eUrinary Bladder Wall\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e4.52E-02\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eKidneys\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e6.55E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eUterus\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e5.50E-03\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLiver\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e3.43E-03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e\u003cp\u003e\u003cb\u003eTotal Body\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e\u003cp\u003e\u003cb\u003e3.20E-03\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e\u003cp\u003e\u003cb\u003eEffective Dose\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e\u003cp\u003e\u003cb\u003e4.60E-03\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\n\u003ch3\u003ePharmacology and Toxicology Studies\u003c/h3\u003e\n\u003cp\u003eA single-species pharm-tox study to assess preclinical safety of COU was conducted in Sprague-Dawley rats. Rodents were given either a single injection of 86 \u0026micro;g/kg of COU (100x the anticipated dose for future clinical PET imaging studies) (18 male, 18 female) or 5% ethanol in saline vehicle (4 male, 4 female) and sacrificed either 2-4- or 15-days post-injection to look for acute or sub-acute effects, respectively.\u003c/p\u003e\u003cp\u003eParameters for evaluation included clinical observations, body weights, food intake, and physical examinations, including ophthalmology. Additionally, organ weights were recorded and gross (macroscopic) pathological examinations were performed on all study animals at necropsy. Hematology and clinical chemistry evaluations were performed on blood samples collected from all study animals just prior to necropsy. Histopathological (microscopic) examinations were performed on the tissues collected at necropsy.\u003c/p\u003e\u003cp\u003eAll measurements taken during this study were within normal limits and no drug-related adverse reactions were reported and no drug-related clinical findings. Body weight stayed steady through the study with a mean weight of 211 g at baseline and 285 g on day 15 for males and 214 g at baseline and 233 g on day 15 for females. This increase follows normal weight gain for rats\u003csup\u003e\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e\u003c/sup\u003e. Food consumption also stayed consistent with an average of 21.9\u0026thinsp;\u0026plusmn;\u0026thinsp;1.8 g/day for males and 17.2\u0026thinsp;\u0026plusmn;\u0026thinsp;1.6 g/day for females. All organs measured weighed similar from day 2\u0026ndash;4 to day 15. All blood chemistry measurements and blood cell counts were not significantly changed between days 2\u0026ndash;4 and 15. In the animals sacrificed at days 2\u0026ndash;4, a low grade intermyelinic edema was observed. In a supplemental study, this was investigated further and since both vehicle- and COU-treated animals had similar brain lesions, it was determined that these lesions were not directly COU related (see Supplementary Information). Instead, the vacuolation in brain appears to be vehicle‐related or to be due to specimen processing. White matter vacuolation is a very common postmortem artifact associated with fixation if there is excessive exposure to alcohol (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://ntp.niehs.nih.gov/nnl/nervous/brain/index.htm\u003c/span\u003e\u003cspan address=\"https://ntp.niehs.nih.gov/nnl/nervous/brain/index.htm\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e). The fact that formulated COU and vehicle both contained 5% ethanol USP (v/v), offers a possible explanation for this finding.\u003c/p\u003e\u003cp\u003eFrom this study, COU was determined to have a safety profile appropriate for clinical translation, with a maximum tolerated dose of COU\u0026thinsp;\u0026ge;\u0026thinsp;86 \u0026micro;g/kg given as a single intravenous injection. This corresponds to the human equivalent dose being \u0026ge;\u0026thinsp;14 \u0026micro;g/kg. From the toxicology analysis, the effective dose for use in future clinical studies with [\u003csup\u003e11\u003c/sup\u003eC]COU was set to \u0026le;\u0026thinsp;0.14 \u0026micro;g/kg, 100 x below the NOAEL limit estimated from the rodent pharmacology \u0026ndash; toxicology studies.\u003c/p\u003e"},{"header":"MATERIALS AND METHODS","content":"\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e\u003ch2\u003eSynthesis Validation\u003c/h2\u003e\u003cdiv id=\"Sec8\" class=\"Section3\"\u003e\u003ch2\u003eGeneral Considerations\u003c/h2\u003e\u003cp\u003eDetailed experimental protocol, including mass spectrometry, nuclear magnetic resonance (NMR) spectra, semi-preparative and analytical high-performance liquid chromatography (HPLC) traces, are provided in the Supporting Information accompanying this article.\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\n\u003ch3\u003eLarge Scale Synthesis of COU Precursor and Standard\u003c/h3\u003e\n\u003cp\u003eTo aide in clinical translation, the synthesis of COU precursor and standard were modified to gram scale. This was done with optimization of the synthesis reported in Brooks, et. al. 2020\u003csup\u003e51\u003c/sup\u003e. We synthesized 421 mg of precursor at 97% purity and 378 mg of standard using the procedure reported by Brooks, et. el., 2015\u003csup\u003e46\u003c/sup\u003e (see see Supplemental Information for more information). Both the standard and precursor lots were analyzed by NMR and analytical HPLC annually for purity and repurified when necessary. These compounds were then aliquoted into 1 mg lots and stored in a -20 ℃ freezer until use.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eRadiosynthesis of [\u003c/em\u003e\u003csup\u003e\u003cem\u003e11\u003c/em\u003e\u003c/sup\u003e\u003cem\u003eC]COU\u003c/em\u003e: Production of \u003csup\u003e11\u003c/sup\u003eC-labeled radiotracers conducted using General Electric (GE) TRACERLab FX\u003csub\u003eC-Pro\u003c/sub\u003e automated radiochemistry synthesis module. [\u003csup\u003e11\u003c/sup\u003eC]Carbon dioxide ([\u003csup\u003e11\u003c/sup\u003eC]CO\u003csub\u003e2\u003c/sub\u003e) was produced via \u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003eN(p,α)\u003csup\u003e11\u003c/sup\u003eC nuclear reaction using a GE PET Trace cyclotron (60 \u0026micro;A beam for 30 min) and converted by standard procedures into \u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003eC-labeled methyl triflate ([\u003csup\u003e11\u003c/sup\u003eC]CH\u003csub\u003e3\u003c/sub\u003eOTf) from \u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003eC-labeled methyl iodine ([\u003csup\u003e11\u003c/sup\u003eC]CH\u003csub\u003e3\u003c/sub\u003eI) (700 mCi for 30 minute beam). COU precursor (1 mg) was dissolved in DMSO (100 \u0026micro;L) and added to TRACERLab reactor. [\u003csup\u003e11\u003c/sup\u003eC]CH\u003csub\u003e3\u003c/sub\u003eOTf was bubbled through the precursor solution for 3 minutes at room temperature at a rate of 15 mL/min. HPLC buffer (1 mL, 50% MeCN:H\u003csub\u003e2\u003c/sub\u003eO, 50 mM NH\u003csub\u003e4\u003c/sub\u003eHCO\u003csub\u003e3\u003c/sub\u003e, pH 10) was then added to dilute and quench the reaction mixture. The crude reaction mixture was purified using semi-preparative HPLC (column: Gemini 250x10 mm-5\u0026micro; Luna C18, flow rate: 4 mL/min; 50% MeCN:H\u003csub\u003e2\u003c/sub\u003eO, 50 mM NH\u003csub\u003e4\u003c/sub\u003eHCO\u003csub\u003e3\u003c/sub\u003e, pH 10). The peak corresponding to [\u003csup\u003e11\u003c/sup\u003eC]COU was collected and reformulated by diluting in 50 mL of water and trapping the product on a C18 1cc solid phase extraction (SPE) cartridge. Following trapping, the SPE cartridge was rinsed with water (5 mL) to remove residual MeCN. [\u003csup\u003e11\u003c/sup\u003eC]COU was then eluted with ethanol USP (0.5 mL) and diluted with saline USP (9.5 mL) to produce a formulated dose (5% ethanol in saline) that was then filtered through a 0.22 \u0026micro;m sterile filter into a sterile vial. Following terminal sterilization, a sample (0.5 mL) is removed from the batch and submitted for quality control (QC) testing as described below. The process is accomplished in an overall synthesis times of 30 min from end-of-bombardment (EOB).\u003c/p\u003e\n\u003ch3\u003eQuality Control\u003c/h3\u003e\n\u003cp\u003eAll quality control analyses were performed according to requirements described in US Pharmacopeia Chapter\u0026thinsp;\u0026lt;\u0026thinsp;823\u0026thinsp;\u0026gt;\u0026thinsp;and United States Code 21 USC 321. All release criteria are shown with acceptable thresholds along with a pass/fail qualification in Table\u0026nbsp;1.\u003c/p\u003e\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\u003ch2\u003eAnalytical HPLC\u003c/h2\u003e\u003cp\u003eBoth chemical and radiochemical purity were determined using a Shimadzu LC2010 HPLC equipped with a Bioscan/Eckert and Ziegler radioactivity and ultraviolet detector (Column: Gemini NX, 5\u0026micro;, 250 x 4.6 mm, flow rate: 1 mL/min, mobile phase: 50% MeCN:H\u003csub\u003e2\u003c/sub\u003eO, 50 mM NH\u003csub\u003e4\u003c/sub\u003eHCO\u003csub\u003e3\u003c/sub\u003e, pH: 10, t\u003csub\u003eR\u003c/sub\u003e: 5.75\u0026thinsp;\u0026plusmn;\u0026thinsp;0.1 min).\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e\u003ch2\u003epH Test\u003c/h2\u003e\u003cp\u003eThe pH of the formulated dose of [\u003csup\u003e11\u003c/sup\u003eC]COU was analyzed by placing a sample of the dose on a pH indicator strip. The indicator was then compared to the provided reference to determine the pH.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e\u003ch2\u003eFilter Integrity Test\u003c/h2\u003e\u003cp\u003eThe sterile filter attached to the final dose vial was removed from the hot-cell. The filter and needle were then attached to a nitrogen supply with a pressure regulator. The needle was submerged in water and the nitrogen pressure was slowly increased. The pressure is increased until bubbles appear in the water (the bubble point). This pressure is then recorded.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec14\" class=\"Section2\"\u003e\u003ch2\u003eEndotoxin Test\u003c/h2\u003e\u003cp\u003eEndotoxins were measured using a Charles River EndoSafe Portable Testing System. This is performed by adding a small amount of the formulated [\u003csup\u003e11\u003c/sup\u003eC]COU dose into the reservoir on the PTS cartridge to detect the amount of endotoxins in the sample.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec15\" class=\"Section2\"\u003e\u003ch2\u003eSterility Test\u003c/h2\u003e\u003cp\u003eFluid thioglycolate media (FTM) and soybean casein digest agar media (SCDM) culture tubes were utilized for evaluation of the sterility of [\u003csup\u003e11\u003c/sup\u003eC]COU doses. The culture tubes were inoculated with dose samples then incubated at 20\u0026ndash;25℃ (FTM) or 30\u0026ndash;35℃ (SCDM) for 14 days alongside both positive and negative controls. The culture tubes were inspected visually at 3-, 8-, and 14-days post-inoculation. Sterility was confirmed based on the visual determination of turbidity in the samples based on both the positive and negative controls.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec16\" class=\"Section2\"\u003e\u003ch2\u003eBiodistribution and Dosimetry\u003c/h2\u003e\u003cp\u003eMale (n\u0026thinsp;=\u0026thinsp;2) and female (n\u0026thinsp;=\u0026thinsp;2) Sprague Dawley (SD) rats weighing 161\u0026ndash;251 g were anesthetized using isoflurane and subsequently injected with 150\u0026ndash;500 \u0026micro;Ci of [\u003csup\u003e11\u003c/sup\u003eC]COU via femoral vein. Pressure was applied to the injection site to stop bleeding. The rats were allowed to recover from the anesthetic and resume normal activity. Each animal was sacrificed by decapitation at either 10, 20, 60, or 120 min post injection. Tissues and fluids were excised, homogenized, and counted for radioactivity in an auto-gamma counter to determine dosimetry and biodistribution. The results were corrected for radioactive decay and expressed in terms of percent-injected dose per gram of tissue (%ID/g) (see Supplemental Information and Supplemental Table\u0026nbsp;1 for more information).\u003c/p\u003e\u003cp\u003eThe biodistribution data was used to estimate human internal radiation dosimetry, calculated from rat biodistribution using the MIRD formalism (see Supplemental Information and Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e2\u003c/span\u003e for more information).\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec17\" class=\"Section2\"\u003e\u003ch2\u003ePharmacology and Toxicology Studies\u003c/h2\u003e\u003cp\u003ePharmacology and Toxicology studies were conducted at the Michigan State University In Vivo facility in Sprague Dawley rats. Rodents were housed individually and given free access to rodent chow and water. Animals were housed individually in plastic solid-bottom cages with aspen bedding throughout the duration of the study. In addition, animals had access to fresh water and were provided standard rodent chow in sufficient amounts to ensure ad libitum consumption. Sprague-Dawley rats were obtained from Charles River Laboratories and after approx. 1 week of acclimation, body weights were recorded [184\u0026ndash;335 grams (males) or 200\u0026ndash;249 grams (females)] at the time of dosing initiation. Light anesthesia was carried out using isoflurane, and then blood (~\u0026thinsp;1 mL total) was collected into K\u003csub\u003e3\u003c/sub\u003eEDTA and serum tubes and was then processed for clinical chemistry and complete blood count (CBC) baseline measurements.\u003c/p\u003e\u003cp\u003eThe animals were given either a single \u003cem\u003ei.v.\u003c/em\u003e injection of 86 \u0026micro;g/kg of COU (100x the expected dose for PET imaging study) (18 male, 18 female) or 5% ethanol in saline vehicle (4 male, 4 female) and sacrificed either 2-4- or 15-days post-injection to look for acute or sub-acute effects, respectively. Throughout the study, food intake was periodically monitored. Additional blood samples were collected just prior to sacrifice for repeat CBC analysis. Following euthanasia, terminal body weights were obtained. Various tissues of interest (i.e. heart, kidneys, liver, and brain) were measured and fixed in 10% neutral-buffered formalin. Slides were prepared, stained with standard Hematoxylin and Eosin, and reviewed by a qualified veterinary pathologist.\u003c/p\u003e\u003c/div\u003e"},{"header":"CONCLUSIONS","content":"\u003cp\u003eIn this work, the radiosynthesis of [\u003csup\u003e11\u003c/sup\u003eC]COU has been validated, providing formulated product in acceptable yields, purities, molar activities, and sterility suitable for routine clinical use. Dosimetric studies have determined that, at a dose of 18 mCi, human subjects can receive two doses of [\u003csup\u003e11\u003c/sup\u003eC]COU without exceeding safe dose limits. From our pharmacology and toxicology studies we concluded that the maximum tolerated dose of COU was \u0026ge;\u0026thinsp;86 \u0026micro;g/kg in Sprague Dawley rats. Human estimated maximum dose was set to \u0026ge;\u0026thinsp;14 \u0026micro;g/kg based on the rodent studies, and the set dose for clinical trials is \u0026le;\u0026thinsp;0.14 \u0026micro;g/kg, 100-fold below the estimated maximum dose. From these preclinical studies, it can be concluded that [\u003csup\u003e11\u003c/sup\u003eC]COU is safe for translation into clinical studies. To this end, our lab has recently begun first-in-human studies using [\u003csup\u003e11\u003c/sup\u003eC]COU under the approval of the US Food and Drug Administration and the Michigan Medicine Institutional Review Board. These clinical studies are ongoing, and will be reported out in due course.\u003c/p\u003e\u003cdiv id=\"Sec19\" class=\"Section2\"\u003e\u003ch2\u003eASSOCIATED CONTENT\u003c/h2\u003e\u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003ch2\u003eDEDICATION\u003c/h2\u003e\u003cp\u003eWe dedicate this paper to Prof. George A. Garcia on the occasion of his retirement. Congratulations on an illustrious career in medicinal chemistry, and many thanks for your support of Prof. Scott and the UM PET Program throughout the years.\u003c/p\u003e\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eThe manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.\u003c/p\u003e\u003ch2\u003eAcknowledgement\u003c/h2\u003e\u003cp\u003eThis work was supported by the NIH [R21NS075553 (M.R.K.); R21AG073686 (P.J.H.S. and K.A.F.)] as well as the University of Michigan (Department of Radiology and SOAR). We also thank Teresa Krieger-Burke, DVM, PhD, Dept of Pharmacology \u0026amp; Toxicology at Michigan State University, for her valuable assistance with the COU pharmacology and toxicology study.\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003eData is provided within the manuscript or supplementary information.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003e2025 Alzheimer\u0026rsquo;s Disease Facts and Figures. \u003cem\u003eAlzheimers Dement.\u003c/em\u003e 2025, \u003cem\u003e21\u003c/em\u003e (4), e70235. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/alz.70235\u003c/span\u003e\u003cspan address=\"10.1002/alz.70235\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTeipel, S.; Gustafson, D.; Ossenkoppele, R.; Hansson, O.; Babiloni, C.; Wagner, M.; Riedel-Heller, S. G.; Kilimann, I.; Tang, Y. Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention. \u003cem\u003eJ. Nucl. Med.\u003c/em\u003e 2022, \u003cem\u003e63\u003c/em\u003e (7), 981\u0026ndash;985. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2967/jnumed.121.262239\u003c/span\u003e\u003cspan address=\"10.2967/jnumed.121.262239\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCohen, B. M.; Sonntag, K.-C. Identifying the Earliest-Occurring Clinically Targetable Precursors of Late-Onset Alzheimer\u0026rsquo;s Disease. \u003cem\u003eeBioMedicine\u003c/em\u003e 2024, \u003cem\u003e106\u003c/em\u003e, 105238. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.ebiom.2024.105238\u003c/span\u003e\u003cspan address=\"10.1016/j.ebiom.2024.105238\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCarter, S. F.; Sch\u0026ouml;ll, M.; Almkvist, O.; Wall, A.; Engler, H.; L\u0026aring;ngstr\u0026ouml;m, B.; Nordberg, A. Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by \u003csup\u003e11\u003c/sup\u003e C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining \u003csup\u003e11\u003c/sup\u003e C-Pittsburgh Compound B and \u003csup\u003e18\u003c/sup\u003e F-FDG. \u003cem\u003eJ. Nucl. Med.\u003c/em\u003e 2012, \u003cem\u003e53\u003c/em\u003e (1), 37\u0026ndash;46. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2967/jnumed.110.087031\u003c/span\u003e\u003cspan address=\"10.2967/jnumed.110.087031\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBenzinger, T. L. S.; Blazey, T.; Jack, C. R.; Koeppe, R. A.; Su, Y.; Xiong, C.; Raichle, M. E.; Snyder, A. Z.; Ances, B. M.; Bateman, R. J.; Cairns, N. J.; Fagan, A. M.; Goate, A.; Marcus, D. S.; Aisen, P. S.; Christensen, J. J.; Ercole, L.; Hornbeck, R. C.; Farrar, A. M.; Aldea, P.; Jasielec, M. S.; Owen, C. J.; Xie, X.; Mayeux, R.; Brickman, A.; McDade, E.; Klunk, W.; Mathis, C. A.; Ringman, J.; Thompson, P. M.; Ghetti, B.; Saykin, A. J.; Sperling, R. A.; Johnson, K. A.; Salloway, S.; Correia, S.; Schofield, P. R.; Masters, C. L.; Rowe, C.; Villemagne, V. L.; Martins, R.; Ourselin, S.; Rossor, M. N.; Fox, N. C.; Cash, D. M.; Weiner, M. W.; Holtzman, D. M.; Buckles, V. D.; Moulder, K.; Morris, J. C. Regional Variability of Imaging Biomarkers in Autosomal Dominant Alzheimer\u0026rsquo;s Disease. \u003cem\u003eProc. Natl. Acad. Sci.\u003c/em\u003e 2013, \u003cem\u003e110\u003c/em\u003e (47), E4502\u0026ndash;E4509. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1073/pnas.1317918110\u003c/span\u003e\u003cspan address=\"10.1073/pnas.1317918110\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVillemagne, V. L.; Burnham, S.; Bourgeat, P.; Brown, B.; Ellis, K. A.; Salvado, O.; Szoeke, C.; Macaulay, S. L.; Martins, R.; Maruff, P.; Ames, D.; Rowe, C. C.; Masters, C. L. Amyloid β Deposition, Neurodegeneration, and Cognitive Decline in Sporadic Alzheimer\u0026rsquo;s Disease: A Prospective Cohort Study. \u003cem\u003eLancet Neurol.\u003c/em\u003e 2013, \u003cem\u003e12\u003c/em\u003e (4), 357\u0026ndash;367. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/S1474-4422(13)70044-9\u003c/span\u003e\u003cspan address=\"10.1016/S1474-4422(13)70044-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRodriguez-Vieitez, E.; Saint-Aubert, L.; Carter, S. F.; Almkvist, O.; Farid, K.; Sch\u0026ouml;ll, M.; Chiotis, K.; Thordardottir, S.; Graff, C.; Wall, A.; L\u0026aring;ngstr\u0026ouml;m, B.; Nordberg, A. Diverging Longitudinal Changes in Astrocytosis and Amyloid PET in Autosomal Dominant Alzheimer\u0026rsquo;s Disease. \u003cem\u003eBrain\u003c/em\u003e 2016, \u003cem\u003e139\u003c/em\u003e (3), 922\u0026ndash;936. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/brain/awv404\u003c/span\u003e\u003cspan address=\"10.1093/brain/awv404\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNarayanaswami, V.; Dahl, K.; Bernard-Gauthier, V.; Josephson, L.; Cumming, P.; Vasdev, N. Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO. \u003cem\u003eMol. Imaging\u003c/em\u003e 2018, \u003cem\u003e17\u003c/em\u003e, 1536012118792317. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1177/1536012118792317\u003c/span\u003e\u003cspan address=\"10.1177/1536012118792317\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKhakh, B. S.; Sofroniew, M. V. Diversity of Astrocyte Functions and Phenotypes in Neural Circuits. \u003cem\u003eNat. Neurosci.\u003c/em\u003e 2015, \u003cem\u003e18\u003c/em\u003e (7), 942\u0026ndash;952. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/nn.4043\u003c/span\u003e\u003cspan address=\"10.1038/nn.4043\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHeneka, M. T.; Carson, M. J.; Khoury, J. E.; Landreth, G. E.; Brosseron, F.; Feinstein, D. L.; Jacobs, A. H.; Wyss-Coray, T.; Vitorica, J.; Ransohoff, R. M.; Herrup, K.; Frautschy, S. A.; Finsen, B.; Brown, G. C.; Verkhratsky, A.; Yamanaka, K.; Koistinaho, J.; Latz, E.; Halle, A.; Petzold, G. C.; Town, T.; Morgan, D.; Shinohara, M. L.; Perry, V. H.; Holmes, C.; Bazan, N. G.; Brooks, D. J.; Hunot, S.; Joseph, B.; Deigendesch, N.; Garaschuk, O.; Boddeke, E.; Dinarello, C. A.; Breitner, J. C.; Cole, G. M.; Golenbock, D. T.; Kummer, M. P. Neuroinflammation in Alzheimer\u0026rsquo;s Disease. \u003cem\u003eLancet Neurol.\u003c/em\u003e 2015, \u003cem\u003e14\u003c/em\u003e (4), 388\u0026ndash;405. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/S1474-4422(15)70016-5\u003c/span\u003e\u003cspan address=\"10.1016/S1474-4422(15)70016-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChaney, A. M.; Deal, E. M.; Jackson, I. M.; James, M. L. PET Imaging of Neuroinflammation. In \u003cem\u003eMolecular Imaging\u003c/em\u003e; Elsevier, 2021; pp 1335\u0026ndash;1371.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChauveau, F.; Winkeler, A.; Chalon, S.; Boutin, H.; Becker, G. PET Imaging of Neuroinflammation: Any Credible Alternatives to TSPO Yet? \u003cem\u003eMol. Psychiatry\u003c/em\u003e 2025, \u003cem\u003e30\u003c/em\u003e (1), 213\u0026ndash;228. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41380-024-02656-9\u003c/span\u003e\u003cspan address=\"10.1038/s41380-024-02656-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGouilly, D.; Saint-Aubert, L.; Ribeiro, M.; Salabert, A.; Tauber, C.; P\u0026eacute;ran, P.; Arlicot, N.; Pariente, J.; Payoux, P. Neuroinflammation PET Imaging of the Translocator Protein (TSPO) in Alzheimer\u0026rsquo;s Disease: An Update. \u003cem\u003eEur. J. Neurosci.\u003c/em\u003e 2022, \u003cem\u003e55\u003c/em\u003e (5), 1322\u0026ndash;1343. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/ejn.15613\u003c/span\u003e\u003cspan address=\"10.1111/ejn.15613\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRossano, S. M.; Johnson, A. S.; Smith, A.; Ziaggi, G.; Roetman, A.; Guzman, D.; Okafor, A.; Klein, J.; Tomljanovic, Z.; Stern, Y.; Brickman, A. M.; Lee, S.; Kreisl, W. C.; Lao, P. Microglia Measured by TSPO PET Are Associated with Alzheimer\u0026rsquo;s Disease Pathology and Mediate Key Steps in a Disease Progression Model. \u003cem\u003eAlzheimers Dement.\u003c/em\u003e 2024, \u003cem\u003e20\u003c/em\u003e (4), 2397\u0026ndash;2407. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/alz.13699\u003c/span\u003e\u003cspan address=\"10.1002/alz.13699\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKim, M.-J.; Anaya, F. J.; Manly, L. S.; Lee, J.-H.; Hong, J.; Shrestha, S.; Telu, S.; Henry, K.; Santamaria, J. A. M.; Liow, J.-S.; Zanotti-Fregonara, P.; Shetty, H. U.; Zoghbi, S. S.; Pike, V. W.; Innis, R. B. Whole-Body PET Imaging in Humans Shows That\u003csup\u003e11\u003c/sup\u003e C-PS13 Is Selective for Cyclooxygenase-1 and Can Measure the In Vivo Potency of Nonsteroidal Antiinflammatory Drugs. \u003cem\u003eJ. Nucl. Med.\u003c/em\u003e 2023, \u003cem\u003e64\u003c/em\u003e (1), 159\u0026ndash;164. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2967/jnumed.122.264061\u003c/span\u003e\u003cspan address=\"10.2967/jnumed.122.264061\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKenou, B. V.; Manly, L. S.; Rubovits, S. B.; Umeozulu, S. A.; Van Buskirk, M. G.; Zhang, A. S.; Pike, V. W.; Zanotti-Fregonara, P.; Henter, I. D.; Innis, R. B. Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia. \u003cem\u003eJ. Nucl. Med.\u003c/em\u003e 2022, \u003cem\u003e63\u003c/em\u003e (Supplement 1), 53S-59S. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2967/jnumed.121.263199\u003c/span\u003e\u003cspan address=\"10.2967/jnumed.121.263199\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGhazanfari, N.; Kim, M.-J.; Knoer, C.; Hong, J.; Ahmadi, F.; Montero Stantamaria, J. A.; Zoghbi, S.; Liow, J.-S.; Pike, V.; Innis, R.; Zanotti-Fregonara, P. [11C]PS13 Shows High Specific and Displaceable Binding to COX-1 Enzyme in the Human Brain; Journal of Nuclear Medicine: P498, 2023; Vol. 64.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKoole, M.; Schmidt, M. E.; Hijzen, A.; Ravenstijn, P.; Vandermeulen, C.; Van Weehaeghe, D.; Serdons, K.; Celen, S.; Bormans, G.; Ceusters, M.; Zhang, W.; Van Nueten, L.; Kolb, H.; De Hoon, J.; Van Laere, K. \u003csup\u003e18\u003c/sup\u003e F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. \u003cem\u003eJ. Nucl. Med.\u003c/em\u003e 2019, \u003cem\u003e60\u003c/em\u003e (5), 683\u0026ndash;690. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2967/jnumed.118.216747\u003c/span\u003e\u003cspan address=\"10.2967/jnumed.118.216747\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHagens, M. H. J.; Golla, S. S. V.; Janssen, B.; Vugts, D. J.; Beaino, W.; Windhorst, A. D.; O\u0026rsquo;Brien-Brown, J.; Kassiou, M.; Schuit, R. C.; Schwarte, L. A.; De Vries, H. E.; Killestein, J.; Barkhof, F.; Van Berckel, B. N. M.; Lammertsma, A. A. The P2X7 Receptor Tracer [11C]SMW139 as an in Vivo Marker of Neuroinflammation in Multiple Sclerosis: A First-in Man Study. \u003cem\u003eEur. J. Nucl. Med. Mol. Imaging\u003c/em\u003e 2020, \u003cem\u003e47\u003c/em\u003e (2), 379\u0026ndash;389. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s00259-019-04550-x\u003c/span\u003e\u003cspan address=\"10.1007/s00259-019-04550-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBrumberg, J.; Aarnio, R.; Forsberg, A.; Marjam\u0026auml;ki, P.; Kerstens, V.; Moein, M. M.; Nag, S.; Wahlroos, S.; Kassiou, M.; Windhorst, A. D.; Halldin, C.; Haaparanta-Solin, M.; Fazio, P.; Oikonen, V.; Rinne, J. O.; Varrone, A. Quantification of the Purinergic P2X\u003csub\u003e7\u003c/sub\u003e Receptor with [\u003csup\u003e11\u003c/sup\u003e C]SMW139 Improves through Correction for Brain-Penetrating Radiometabolites. \u003cem\u003eJ. Cereb. Blood Flow Metab.\u003c/em\u003e 2023, \u003cem\u003e43\u003c/em\u003e (2), 258\u0026ndash;268. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1177/0271678X221126830\u003c/span\u003e\u003cspan address=\"10.1177/0271678X221126830\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChen, J.; Collier, T.; Levey, A.; Schuster, D.; Liang, S. Evaluation of P2X\u0026amp; PET Tracer [18F]JNJ-64413739 on Postmortem Alzheimer\u0026rsquo;s Disease Human Brain Tissue; Journal of Nuclear Medicine: P794, 2023; Vol. 64.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLiu, Y.; Jiang, H.; Qin, X.; Tian, M.; Zhang, H. PET Imaging of Reactive Astrocytes in Neurological Disorders. \u003cem\u003eEur. J. Nucl. Med. Mol. Imaging\u003c/em\u003e 2022, \u003cem\u003e49\u003c/em\u003e (4), 1275\u0026ndash;1287. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s00259-021-05640-5\u003c/span\u003e\u003cspan address=\"10.1007/s00259-021-05640-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGuilarte, T. R. TSPO in Diverse CNS Pathologies and Psychiatric Disease: A Critical Review and a Way Forward. \u003cem\u003ePharmacol. Ther.\u003c/em\u003e 2019, \u003cem\u003e194\u003c/em\u003e, 44\u0026ndash;58. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.pharmthera.2018.09.003\u003c/span\u003e\u003cspan address=\"10.1016/j.pharmthera.2018.09.003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNarayanaswami, V.; Drake, L. R.; Brooks, A. F.; Meyer, J. H.; Houle, S.; Kilbourn, M. R.; Scott, P. J. H.; Vasdev, N. Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases. \u003cem\u003eACS Chem. Neurosci.\u003c/em\u003e 2019, \u003cem\u003e10\u003c/em\u003e (4), 1867\u0026ndash;1871. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1021/acschemneuro.9b00081\u003c/span\u003e\u003cspan address=\"10.1021/acschemneuro.9b00081\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSegura-Aguilar, J. Dopamine Oxidative Deamination. In \u003cem\u003eClinical Studies and Therapies in Parkinson\u0026rsquo;s Disease\u003c/em\u003e; Elsevier, 2021; pp 203\u0026ndash;207. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/B978-0-12-822120-4.00006-X\u003c/span\u003e\u003cspan address=\"10.1016/B978-0-12-822120-4.00006-X\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWestlund, K. N.; Denney, R. M.; Kochersperger, L. M.; Rose, R. M.; Abell, C. W. Distinct Monoamine Oxidase A and B Populations in Primate Brain. \u003cem\u003eScience\u003c/em\u003e 1985, \u003cem\u003e230\u003c/em\u003e (4722), 181\u0026ndash;183. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1126/science.3875898\u003c/span\u003e\u003cspan address=\"10.1126/science.3875898\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFowler, J. S.; MacGregor, R. R.; Wolf, A. P.; Arnett, C. D.; Dewey, S. L.; Schlyer, D.; Christman, D.; Logan, J.; Smith, M.; Sachs, H.; Aquilonius, S. M.; Bjurling, P.; Halldin, C.; Hartvig, P.; Leenders, K. L.; Lundqvist, H.; Oreland, L.; St\u0026aring;lnacke, C.-G.; L\u0026aring;ngstr\u0026ouml;m, B. Mapping Human Brain Monoamine Oxidase A and B with\u003csup\u003e11\u003c/sup\u003e C-Labeled Suicide Inactivators and PET. \u003cem\u003eScience\u003c/em\u003e 1987, \u003cem\u003e235\u003c/em\u003e (4787), 481\u0026ndash;485. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1126/science.3099392\u003c/span\u003e\u003cspan address=\"10.1126/science.3099392\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMacgregor, R. R.; Fowler, J. S.; Wolf, A. P.; Halldin, C.; Langstr\u0026ouml;m, B. Synthesis of Suicide Inhibitors of Monoamine Oxidase: Carbon-11 Labeled Clorgyline, L-Deprenyl and D-Deprenyl. \u003cem\u003eJ. Label. Compd. Radiopharm.\u003c/em\u003e 1988, \u003cem\u003e25\u003c/em\u003e (1), 1\u0026ndash;9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/jlcr.2580250102\u003c/span\u003e\u003cspan address=\"10.1002/jlcr.2580250102\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFowler, J. S.; Wang, G.-J.; Logan, J.; Xie, S.; Volkow, N. D.; MacGregor, R. R.; Schlyer, D. J.; Pappas, N.; Alexoff, D. L.; Patlak, C.; Wolf, A. P. Selective Reduction of Radiotracer Trapping by Deuterium Substitution: Comparison of Carbon-11-L-Deprenyl and Carbon-11-Deprenyl-D2 for MAo-B Mapping. \u003cem\u003eJ. Nucl. Med.\u003c/em\u003e 1995, \u003cem\u003e36\u003c/em\u003e (7), 1255\u0026ndash;1262.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFowler, J. S.; Wolf, A. P.; MacGregor, R. R.; Dewey, S. L.; Logan, J.; Schlyer, D. J.; Langstrom, B. Mechanistic Positron Emission Tomography Studies: Demonstration of a Deuterium Isotope Effect in the Monoamine Oxidase-Catalyzed Binding of [\u003csup\u003e11\u003c/sup\u003e C]l‐Deprenyl in Living Baboon Brain. \u003cem\u003eJ. Neurochem.\u003c/em\u003e 1988, \u003cem\u003e51\u003c/em\u003e (5), 1524\u0026ndash;1534. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/j.1471-4159.1988.tb01121.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1471-4159.1988.tb01121.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eArnett, C. D.; Fowler, J. S.; MacGregor, R. R.; Schlyer, D. J.; Wolf, A. P.; L\u0026aring;ngstr\u0026ouml;m, B.; Halldin, C. Turnover of Brain Monoamine Oxidase Measured In Vivo by Positron Emission Tomography Using l -[\u003csup\u003e11\u003c/sup\u003e C]Deprenyl. \u003cem\u003eJ. Neurochem.\u003c/em\u003e 1987, \u003cem\u003e49\u003c/em\u003e (2), 522\u0026ndash;527. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/j.1471-4159.1987.tb02895.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1471-4159.1987.tb02895.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBallweg, A.; Klaus, C.; Vogler, L.; Katzdobler, S.; Wind, K.; Zatcepin, A.; Ziegler, S. I.; Secgin, B.; Eckenweber, F.; Bohr, B.; Bernhardt, A.; Fietzek, U.; Rauchmann, B.-S.; Stoecklein, S.; Quach, S.; Beyer, L.; Scheifele, M.; Simmet, M.; Joseph, E.; Lindner, S.; Berg, I.; Koglin, N.; Mueller, A.; Stephens, A. W.; Bartenstein, P.; Tonn, J. C.; Albert, N. L.; K\u0026uuml;mpfel, T.; Kerschensteiner, M.; Perneczky, R.; Levin, J.; Paeger, L.; Herms, J.; Brendel, M. [18F]F-DED PET Imaging of Reactive Astrogliosis in Neurodegenerative Diseases: Preclinical Proof of Concept and First-in-Human Data. \u003cem\u003eJ. Neuroinflammation\u003c/em\u003e 2023, \u003cem\u003e20\u003c/em\u003e (1), 68. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s12974-023-02749-2\u003c/span\u003e\u003cspan address=\"10.1186/s12974-023-02749-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRusjan, P. M.; Wilson, A. A.; Miler, L.; Fan, I.; Mizrahi, R.; Houle, S.; Vasdev, N.; Meyer, J. H. Kinetic Modeling of the Monoamine Oxidase B Radioligand [11C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography. \u003cem\u003eJ. Cereb. Blood Flow Metab.\u003c/em\u003e 2014, \u003cem\u003e34\u003c/em\u003e (5), 883\u0026ndash;889. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/jcbfm.2014.34\u003c/span\u003e\u003cspan address=\"10.1038/jcbfm.2014.34\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBraga, J.; Kuik, E. J. Y.; Lepra, M.; Rusjan, P. M.; Kish, S. J.; Vieira, E. L.; Nasser, Z.; Verhoeff, N.; Vasdev, N.; Chao, T.; Bagby, M.; Boileau, I.; Kloiber, S.; Husain, M. I.; Kolla, N.; Koshimori, Y.; Faiz, K.; Wang, W.; Meyer, J. H. Astrogliosis Marker [11C]SL25.1188 After COVID-19 With Ongoing Depressive and Cognitive Symptoms. \u003cem\u003eBiol. Psychiatry\u003c/em\u003e 2024, S0006322324016561. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.biopsych.2024.09.027\u003c/span\u003e\u003cspan address=\"10.1016/j.biopsych.2024.09.027\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGill, T.; Watling, S. E.; Richardson, J. D.; McCluskey, T.; Tong, J.; Meyer, J. H.; Warsh, J.; Jetly, R.; Hutchison, M. G.; Rhind, S. G.; Houle, S.; Vasdev, N.; Kish, S. J.; Boileau, I. Imaging of Astrocytes in Posttraumatic Stress Disorder: A PET Study with the Monoamine Oxidase B Radioligand [11C]SL25.1188. \u003cem\u003eEur. Neuropsychopharmacol.\u003c/em\u003e 2022, \u003cem\u003e54\u003c/em\u003e, 54\u0026ndash;61. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.euroneuro.2021.10.006\u003c/span\u003e\u003cspan address=\"10.1016/j.euroneuro.2021.10.006\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKoshimori, Y.; Cusimano, M. D.; Vieira, E. L.; Rusjan, P. M.; Kish, S. J.; Vasdev, N.; Moriguchi, S.; Boileau, I.; Chao, T.; Nasser, Z.; Ishrat Husain, M.; Faiz, K.; Braga, J.; Meyer, J. H. Astrogliosis Marker 11C-SL25.1188 PET in Traumatic Brain Injury with Persistent Symptoms. \u003cem\u003eBrain\u003c/em\u003e 2023, \u003cem\u003e146\u003c/em\u003e (11), 4469\u0026ndash;4475. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/brain/awad279\u003c/span\u003e\u003cspan address=\"10.1093/brain/awad279\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eIshibashi, K. Clinical Application of MAO-B PET Using \u003csup\u003e18\u003c/sup\u003e F‐THK5351 in Neurological Disorders. \u003cem\u003eGeriatr. Gerontol. Int.\u003c/em\u003e 2024, \u003cem\u003e24\u003c/em\u003e (S1), 31\u0026ndash;43. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/ggi.14729\u003c/span\u003e\u003cspan address=\"10.1111/ggi.14729\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVillemagne, V. L.; Harada, R.; Dor\u0026eacute;, V.; Furumoto, S.; Mulligan, R.; Kudo, Y.; Burnham, S.; Krishnadas, N.; Bozinovski, S.; Huang, K.; Lopresti, B. J.; Yanai, K.; Rowe, C. C.; Okamura, N. First-in-Humans Evaluation of\u003csup\u003e18\u003c/sup\u003e F-SMBT-1, a Novel\u003csup\u003e18\u003c/sup\u003e F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis. \u003cem\u003eJ. Nucl. Med.\u003c/em\u003e 2022, \u003cem\u003e63\u003c/em\u003e (10), 1551\u0026ndash;1559. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2967/jnumed.121.263254\u003c/span\u003e\u003cspan address=\"10.2967/jnumed.121.263254\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVillemagne, V. L.; Harada, R.; Dor\u0026eacute;, V.; Furumoto, S.; Mulligan, R.; Kudo, Y.; Burnham, S.; Krishnadas, N.; Bourgeat, P.; Xia, Y.; Laws, S.; Bozinovski, S.; Huang, K.; Ikonomovic, M. D.; Fripp, J.; Yanai, K.; Okamura, N.; Rowe, C. C. Assessing Reactive Astrogliosis with 18F-SMBT-1 Across the Alzheimer Disease Spectrum. \u003cem\u003eJ. Nucl. Med.\u003c/em\u003e 2022, \u003cem\u003e63\u003c/em\u003e (10), 1560\u0026ndash;1569. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2967/jnumed.121.263255\u003c/span\u003e\u003cspan address=\"10.2967/jnumed.121.263255\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLinnerbauer, M.; Rothhammer, V. Protective Functions of Reactive Astrocytes Following Central Nervous System Insult. \u003cem\u003eFront. Immunol.\u003c/em\u003e 2020, \u003cem\u003e11\u003c/em\u003e, 573256. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fimmu.2020.573256\u003c/span\u003e\u003cspan address=\"10.3389/fimmu.2020.573256\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhang, W.; Xiao, D.; Mao, Q.; Xia, H. Role of Neuroinflammation in Neurodegeneration Development. \u003cem\u003eSignal Transduct. Target. Ther.\u003c/em\u003e 2023, \u003cem\u003e8\u003c/em\u003e (1), 267. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41392-023-01486-5\u003c/span\u003e\u003cspan address=\"10.1038/s41392-023-01486-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKuhl, D. E.; Koeppe, R. A.; Minoshima, S.; Snyder, S. E.; Ficaro, E. P.; Foster, N. L.; Frey, K. A.; Kilbourn, M. R. In Vivo Mapping of Cerebral Acetylcholinesterase Activity in Aging and Alzheimer\u0026rsquo;s Disease. \u003cem\u003eNeurology\u003c/em\u003e 1999, \u003cem\u003e52\u003c/em\u003e (4), 691\u0026ndash;691. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1212/WNL.52.4.691\u003c/span\u003e\u003cspan address=\"10.1212/WNL.52.4.691\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKilbourn, M. R.; Snyder, S. E.; Sherman, P. S.; Kuhl, D. E. In Vivo Studies of Acetylcholinesterase Activity Using a Labeled Substrate,N-[11C]Methylpiperdin-4-Yl Propionate ([11C]PMP). \u003cem\u003eSynapse\u003c/em\u003e 1996, \u003cem\u003e22\u003c/em\u003e (2), 123\u0026ndash;131. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/(SICI)1098-2396\u003c/span\u003e\u003cspan address=\"10.1002/(SICI)1098-2396\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e(199602)22:2%253C123::AID-SYN5%253E3.0.CO;2-F.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMinoshima, S.; Cross, D.; Thientunyakit, T.; Foster, N. L.; Drzezga, A. \u003csup\u003e18\u003c/sup\u003e F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies. \u003cem\u003eJ. Nucl. Med.\u003c/em\u003e 2022, \u003cem\u003e63\u003c/em\u003e (Supplement 1), 2S-12S. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2967/jnumed.121.263194\u003c/span\u003e\u003cspan address=\"10.2967/jnumed.121.263194\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eResearch, C. for D. E. and. Review of F-18 Fluoro-2-Deoxyglucose (F-18 FDG) Positron Emission Tomography in the Evaluation of Malignancy - August 4, 1999. \u003cem\u003eFDA\u003c/em\u003e 2018.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBrooks, A. F.; Shao, X.; Quesada, C. A.; Sherman, P.; Scott, P. J. H.; Kilbourn, M. R. In Vivo Metabolic Trapping Radiotracers for Imaging Monoamine Oxidase-A and -B Enzymatic Activity. \u003cem\u003eACS Chem. Neurosci.\u003c/em\u003e 2015, \u003cem\u003e6\u003c/em\u003e (12), 1965\u0026ndash;1971. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1021/acschemneuro.5b00223\u003c/span\u003e\u003cspan address=\"10.1021/acschemneuro.5b00223\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFranot, C.; Mabic, S.; Castagnol Jr, N. Chemical Model Studies on the Monoamine Oxidase-B Catalyzed Oxidation of 4-Substituted 1-Cyclopropyl-1,2,3,6-Tetrahydropyridines. \u003cem\u003eBioorg. Med. Chem.\u003c/em\u003e 1998, \u003cem\u003e6\u003c/em\u003e (3), 283\u0026ndash;291. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/S0968-0896(97)10033-5\u003c/span\u003e\u003cspan address=\"10.1016/S0968-0896(97)10033-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBissel, P.; Bigley, M. C.; Castagnoli, K.; Castagnoli Jr, N. Synthesis and Biological Evaluation of MAO-A Selective 1,4-Disubstituted-1,2,3,6-Tetrahydropyridinyl Substrates. \u003cem\u003eBioorg. Med. Chem.\u003c/em\u003e 2002, \u003cem\u003e10\u003c/em\u003e (9), 3031\u0026ndash;3041. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/S0968-0896(02)00136-0\u003c/span\u003e\u003cspan address=\"10.1016/S0968-0896(02)00136-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDrake, L. R.; Brooks, A. F.; Mufarreh, A. J.; Pham, J. M.; Koeppe, R. A.; Shao, X.; Scott, P. J. H.; Kilbourn, M. R. Deuterium Kinetic Isotope Effect Studies of a Potential in Vivo Metabolic Trapping Agent for Monoamine Oxidase B. \u003cem\u003eACS Chem. Neurosci.\u003c/em\u003e 2018, \u003cem\u003e9\u003c/em\u003e (12), 3024\u0026ndash;3027. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1021/acschemneuro.8b00219\u003c/span\u003e\u003cspan address=\"10.1021/acschemneuro.8b00219\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLangston, J. W. The MPTP Story. \u003cem\u003eJ. Park. Dis.\u003c/em\u003e 2024, \u003cem\u003e7\u003c/em\u003e (Suppl 1), S11\u0026ndash;S19. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3233/JPD-179006\u003c/span\u003e\u003cspan address=\"10.3233/JPD-179006\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBrooks, A. F.; Mufarreh, A. J.; Shao, X.; Kaur, T.; Stauff, J.; Arteaga, J.; Kilbourn, M. R.; Scott, P. J. H. Improved Synthesis of [11C]COU and [11C]PHXY, Evaluation of Neurotoxicity, and Imaging of MAOs in Rodent Heart. \u003cem\u003eACS Med. Chem. Lett.\u003c/em\u003e 2020, \u003cem\u003e11\u003c/em\u003e (11), 2300\u0026ndash;2304. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1021/acsmedchemlett.0c00419\u003c/span\u003e\u003cspan address=\"10.1021/acsmedchemlett.0c00419\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBrooks, A. F.; Drake, L. R.; Shao, X.; Zhao, A.; Scott, P. J. H.; Kilbourn, M. R. Evaluation of Enzyme Substrate Radiotracers as PET/MRS Hybrid Imaging Agents. \u003cem\u003eACS Med. Chem. Lett.\u003c/em\u003e 2018, \u003cem\u003e9\u003c/em\u003e (11), 1140\u0026ndash;1143. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1021/acsmedchemlett.8b00402\u003c/span\u003e\u003cspan address=\"10.1021/acsmedchemlett.8b00402\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eStabin, M. G.; Siegel, J. A. Physical Models and Dose Factors for Use in Internal Dose Assessment. \u003cem\u003eHealth Phys.\u003c/em\u003e 2003, \u003cem\u003e85\u003c/em\u003e (3), 294\u0026ndash;310.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eStabin, M. G. OLINDA/EXM 2\u0026mdash;The Next-Generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine. \u003cem\u003eHealth Phys.\u003c/em\u003e 2023, \u003cem\u003e124\u003c/em\u003e (5), 397. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1097/HP.0000000000001682\u003c/span\u003e\u003cspan address=\"10.1097/HP.0000000000001682\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAlem\u0026aacute;an, C. L.; M\u0026aacute;s, R. M.; Rodeiro, I.; Noa, M.; Hern\u0026aacute;ndez, C.; Men\u0026eacute;ndez, R.; G\u0026aacute;mez, R. Reference Database of the Main Physiological Parameters in Sprague-Dawley Rats from 6 to 32 Months. \u003cem\u003eLab. Anim.\u003c/em\u003e 1998, \u003cem\u003e32\u003c/em\u003e (4), 457\u0026ndash;466. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1258/002367798780599802\u003c/span\u003e\u003cspan address=\"10.1258/002367798780599802\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"medicinal-chemistry-research","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"mcre","sideBox":"Learn more about [Medicinal Chemistry Research](https://www.springer.com/journal/44)","snPcode":"44","submissionUrl":"https://submission.nature.com/new-submission/44/3","title":"Medicinal Chemistry Research","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"PET imaging, Preclinical study, MAO-B, Synthesis validation, Dosimetry, Pharmacology/Toxicology","lastPublishedDoi":"10.21203/rs.3.rs-7762445/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7762445/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e[\u003csup\u003e11\u003c/sup\u003eC]COU is a trapped metabolite radiotracer for \u003cem\u003ein vivo\u003c/em\u003e analysis of Monoamine Oxidase B activity using positron emission tomography (PET) imaging. [\u003csup\u003e11\u003c/sup\u003eC]COU has the potential to quantify astrocytosis in the early stages of Alzheimer\u0026rsquo;s disease, providing an earlier marker of disease than currently available for staging disease progression. Prior preclinical studies have demonstrated the efficacy of this radiotracer in preclinical imaging studies, warranting the translation for clinical evaluation. In this paper, we describe results of the requisite preclinical studies required to obtain approval for translation of [\u003csup\u003e11\u003c/sup\u003eC]COU into first-in-human studies. Development and validation of a production method that conforms to the quality requirements described in the US Pharmacopeia was accomplished, along with preclinical rodent studies to determine human radiation dose estimates and a single acute dose pharmacology and toxicology study to establish that an injected mass dose 100-fold higher than the proposed PET imaging dose was below the no-observed-adverse-effect level (NOAEL). The production method was validated in triplicate, yielding [\u003csup\u003e11\u003c/sup\u003eC]COU in sufficient radiochemical yield (9.3\u0026thinsp;\u0026plusmn;\u0026thinsp;0.008%), radiochemical purity (99.2\u0026thinsp;\u0026plusmn;\u0026thinsp;0.002%) and molar activity (4471\u0026thinsp;\u0026plusmn;\u0026thinsp;1744 Ci/mmol) for routine clinical use, and providing a product that was sterile and met (or exceeded) all quality control requirements for human use. Dosimetric analysis determined that the effective human dose of [\u003csup\u003e11\u003c/sup\u003eC]COU is 0.005mSv/MBq, also acceptable for clinical use. Lastly, no observable adverse effects were noted at 86 \u0026micro;g/kg in rodent toxicology studies (100x the proposed human dose). From these results we received approval to advance [\u003csup\u003e11\u003c/sup\u003eC]COU into clinical studies.\u003c/p\u003e","manuscriptTitle":"IND-Enabling Preclinical Studies of [11C]COU, a Trapped Metabolite PET Radiotracer for Monoamine Oxidase-B","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-24 02:16:39","doi":"10.21203/rs.3.rs-7762445/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-10-06T14:03:51+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-10-06T13:38:57+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-10-06T02:42:53+00:00","index":"","fulltext":""},{"type":"submitted","content":"Medicinal Chemistry Research","date":"2025-10-01T21:10:17+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"medicinal-chemistry-research","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"mcre","sideBox":"Learn more about [Medicinal Chemistry Research](https://www.springer.com/journal/44)","snPcode":"44","submissionUrl":"https://submission.nature.com/new-submission/44/3","title":"Medicinal Chemistry Research","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"2fdb00eb-9174-4b7d-a6b5-b41d4da49a44","owner":[],"postedDate":"October 24th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-11-10T16:03:44+00:00","versionOfRecord":{"articleIdentity":"rs-7762445","link":"https://doi.org/10.1007/s00044-025-03496-0","journal":{"identity":"medicinal-chemistry-research","isVorOnly":false,"title":"Medicinal Chemistry Research"},"publishedOn":"2025-11-05 15:57:19","publishedOnDateReadable":"November 5th, 2025"},"versionCreatedAt":"2025-10-24 02:16:39","video":"","vorDoi":"10.1007/s00044-025-03496-0","vorDoiUrl":"https://doi.org/10.1007/s00044-025-03496-0","workflowStages":[]},"version":"v1","identity":"rs-7762445","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7762445","identity":"rs-7762445","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}